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Osteoporosis is a common senile condition with major public health impact in both genders of all 
races. Very little is known about the natural history and etiology of bone loss, and trabecular and 
cortical volumetric bone mineral density (vBMD) in men, especially in men of African heritage. 
This research project was to evaluate age-related patterns and potential correlates for the 
rate of decline in areal BMD (aBMD) at the proximal femur, and vBMD at the radius and tibia in 
a cohort of Afro-Caribbean men aged 40 and above from the Tobago Bone Health Study. We 
also investigated the genetic associations of variants in a gene involved in the bone 
mineralization process, ectonucleotide pyrophosphatase/ phosphodiesterase 1 (ENPP1), with 
bone loss, aBMD and vBMD. 
 In longitudinal analyses, a significantly greater rate of bone loss was observed in men 
aged 40-45 than those aged 45-49 and 50-54. Thereafter, the rate of bone loss accelerated with 
advancing age. The rate of bone loss was also comparable with those observed in Caucasian 
men. Additionally, we identified low body mass index, weight loss, prostate cancer, and 
treatment for prostate cancer with androgen deprivation (ADT) as potential determinants for 
accelerated bone loss. 
In cross-sectional analyses of vBMD, we observed an early decline of trabecular vBMD 
before age 50 and with a slower decline thereafter into 7th decade. Cortical vMBD, however, 
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appeared to decrease with advancing age in a linear fashion. Correlates of vBMD included 
weight, diabetes, prostate cancer, ADT, cigarette smoking and bone chewing. 
In genetic association study, several variants in the ENPP1 gene were strongly associated 
with bone loss, aBMD or vBMD.  More associations were found with cortical vBMD than with 
the other phenotypes. 
Our findings have important public health relevance as they increase our understanding 
of vBMD and age-related bone loss in an under-studied population. We have also identified a 
novel association of ENPP1 gene variants with bone loss and BMD in this population of African 
heritage. Additional research is needed to better understand the factors related to BMD and bone 
loss in populations of African ancestry, especially the apparent early loss of bone mass.   
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1.0  DISSERTATION OVERVIEW AND OBJECTIVES 
Osteoporosis, a disease defined by low bone mineral density (BMD), has been considered 
a condition that predominantly affects post-menopausal women. An abundance of 
research has been conducted to better understand the etiology and prevention of 
osteoporosis in women. However, men are also affected by osteoporosis and mortality 
associated with osteoporosis-related hip factures appears to be higher among men than 
women (1). Although researchers have recognized the need to be better understand 
skeletal health in men, non-white men have been under-represented in osteoporosis-
related research.  
Areal BMD (aBMD) measured by dual-energy x-ray absorptiometry (DXA) has 
been widely used to quantify bone density. Unlike cross-sectional studies, there are only 
a few longitudinal population-based studies that have examined the patterns and 
magnitude of aBMD changes with aging as well as factors associated with these changes 
in men (2-10). It is important to better understand the patterns and causes of aBMD 
changes to prevent osteoporosis, especially in the less-studied African populations.  
DXA provides a two-dimensional measure of aBMD that is known to be 
confounded by differences in bone size. The use of quantitative computed tomography 
(QCT) provides a three-dimensional measure of true volumetric BMD (vBMD) and also 
enables a separate analysis of bone mass in the cortical and trabecular bone 
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compartments, which were known to have different metabolic characteristics. vBMD 
measures have not yet been well-characterized in the elderly or in subjects of African 
origin.  
Genetic susceptibility also plays a major role in determining bone density. It has 
been estimated that genetic factors contribute to 50-80% of inter-individual variability in 
BMD (11-13). Several candidate genes for BMD and osteoporosis have been identified, 
but most of the research has been conducted in women and Caucasians and focused on 
aBMD. There is substantially less known about the genetics of bone loss and vBMD.  
Therefore, the objectives of this dissertation project were to determine and better 
understand the potential environmental and genetic factors associated with rate of decline 
in aBMD and trabecular and cortical vBMD in men of African heritage. 
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2.0  INTRODUCTION 
2.1 EPIDEMIOLOGY OF OSTEOPOROSIS AND OSTEOPOROTIC 
FRACTURES  
2.1.1 Prevalence of osteoporosis and osteoporotic fractures 
Osteoporosis is a common disorder characterized by compromised bone strength and is a 
strong predictor of fracture risk (14-17). According to the World Health Organization 
(WHO), osteoporosis is clinically defined by a bone mineral density (BMD) more than 
2.5 standard deviations below the gender specific mean BMD of young adults (18). 
Osteoporosis affects 10 million people in the US, and is projected to affect approximately 
14 million adults aged 50 and older by 2020 (19).  
The third National Health and Nutrition Examination Survey (NHANES III, 
1998-1994) also estimated that 13-18% or 4-6 million US non-Hispanic white women 50 
years and older have osteoporosis and 37-50% or 13-17 million have osteopenia (BMD 
between 1 and 2.5 SD below the young adult mean) at the hip. In non-Hispanic white 
men, 1-2 million (3-6%) have osteoporosis and another 8-13 million (28-47%) have 
osteopenia at the hip. Despite the lower prevalence in men than women, the number of 
older men with low BMD is still substantial (20). Although the prevalence of 
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osteoporosis is less well-characterized in non-white populations, studies have shown that 
non-Hispanic whites have a higher prevalence of hip osteoporosis than non-Hispanic 
Blacks for both sexes (20). The prevalence among Mexican Americans is similar or 
slightly smaller than it is in non-Hispanic white women, but is lower than in Non-
Hispanic Black men (20).  
Osteoporosis or low BMD is one of the important risk factors for fractures. 
Osteoporotic fractures were estimated to affect 1.7 million of the world’s population in 
1990. This number is expected to rise to 6.3 million by year 2050 (21). Although the life 
time risk of fracture (including hip, vertebra, and forearm) is higher among women (40%) 
than in men (13%) aged 50 and older, the world wide incidence of hip fracture in men is 
projected to increase  by 310%, compared to 240% in women by the year 2050 (21,22). 
Due to demographic changes throughout the world, the proportion of all hip fractures will 
increase dramatically in areas outside of North American and Europe. In Africa, with the 
increase in total population size, the number of hip fractures in men is expected to 
increase by 216% by 2025 and by 698% by 2050, compared to the number of hip 
fractures in 1990 (23). US Caucasians in general have a higher fracture incidence than 
any other ethnic group. The lower incidence of fractures among Blacks has generally 
been explained by their greater bone density (24).  
2.1.2 Mortality and Morbidity 
Nearly one-third of hip fractures result in nursing home admissions and one-fifth of 
patients with hip fractures die within the year following their fracture (25). Fractures are 
also associated with an increased incidence of morbidity including back pain, kyphosis 
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and disability. Racial differences in mortality and morbidity following hip fractures are 
also observed. African Americans who sustain a hip fracture have increased morbidity 
and nearly twice the mortality as Caucasian Americans (26,27). Despite their lower risk 
of osteoporosis and fractures, men may have a higher mortality risk following a fracture 
than do women (1,27). Furthermore, black and white men have nearly identical mortality 
rates whereas black women may experience a higher mortality rate following a fracture 
than their white counterparts (27). 
2.1.3 Economic Burden 
Osteoporotic fractures cost $17-20 billion annually in the US (21,28). More than 20% of 
the expenditures for treatment of osteoporosis-related fractures were due to fractures in 
men (28,29). Men aged 65 and older accounted for 81% of the total medical cost among 
men. By race, approximately 80% of the costs among men are attributable to fractures in 
white men, who account for 80% of the fractures in men (28). The total cost for 
osteoporotic fractures is projected to approach $25.3 billion by the year 2025 and $50 
billion by the year 2050 (28,30). These direct medical costs represent a greater burden 
than the projected annual cost of stroke, breast cancer, diabetes, or chronic lung disease 
(30). A recent study reported a race-specific increasing economic burden for osteoporotic 
fractures in the US (16). They projected that, by the year 2050, the total cost due to 
fractures will increase 37% in whites, 79% in blacks and 175% in Hispanics from the 
year 2005 (28). Worldwide, the economic burden of osteoporosis parallels that seen in 
the US.  
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2.2 BONE BIOLOGY 
Normal bone consists of matrix (type I collagen and other noncollagenous proteins, 
called osteoid) and mineral (principally an amorphous calcium phosphate) organized into 
a mineralized structure. Bone is a dynamic organ, constantly being remodeled under the 
actions of osteoclasts and osteoblasts. 
2.2.1 Osteoclasts and bone resorption 
The osteoclast arises from hematopoietic stem cells and is a bone lining cell responsible 
for bone resorption. Produced by the stromal cell, macrophage colony stimulating factor 
(M-CSF) is responsible for the differentiation of hematopoietic stem cells into pre-
oseteoclasts. The receptor activator of nuclear factor kappa B (RANK) receptor, and 
receptor activator of nuclear factor kappa B ligand (RANKL) is required for the 
differentiation of osteoclasts. When RANKL activates RANK receptors on the pre-
osteoclasts, the cells fuse and differentiate into mature multinucleared osteoclasts. The 
mature osteoclasts solubilize the mineral and organic constituents of bone matrix by 
synthesizing lysosomal enzymes and activating collagenase. High levels of calcium, 
magnesium, phosphate and products of collagen are released into the extracellular fluid 
as the osteoclasts tunnel into the mineralized bone (31).  
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2.2.2 Osteoblast and bone formation 
The osteoblast is the bone lining cell responsible for the production of the bone matrix 
constituents (collagen and ground substance). Osteoblasts originate from mesenchymal 
stem cells (or bone marrow stromal cells), which can differentiate into either adipocytes 
under the influence of peroxisome proliferator-activated receptors γ2 (PPARγ2) or pre-
osteoblasts under the influence of the transcription factor runt-related transcription factor 
2 (Runx2). The pre-osteoblasts then mature into osteoblasts. The active osteoblasts start 
the bone formation process by producing layers of osteoid and slowly refilling the cavity 
created by osteoclasts (31). 
2.2.3 Bone remodeling 
Bone remodeling is a process involving the coupling of bone resorption and bone 
formation. Packets of bone that are resorbed by osteoclasts are replaced by osteoblasts 
during the formation period. This coupling process is believed to be mediated by humoral 
factors acting through osteoblasts and cells in the osteogenic lineage. There are many 
factors involved in the resorption and formation phases including various cytokines and 
hormones. The following table (Table 2-1) highlights the important factors in bone 
formation and bone resorption and their effects on bone remodeling. 
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Table  2-1 Effects of hormones and cytokines on bone formation and resorption 
Hormones/ Cytokines Effects 
RANKL  
(Receptor Activator of Nuclear 
faktor kappa B ligand) 
Binds to its receptor RANK to stimulate the differentiation of 
osteoclasts. 
RANK  
(Receptor Activator of Nuclear 
faktor kappa B) 
Binds to RANKL to stimulate the differentiation of osteoclasts. 
OPG 
(Osteoprotegrin) 
Acts as a nonsignaling decoy receptor for RANKL to inhibit bone 
resorption. It is a strong inhibitor of osteoclast formation and may 
also suppress the survival of osteoclasts. 
IL-1  
(Interleukin 1) 
A stimulator of osteoclast formation. Also a mediator of bone 
resorption and increased bone turnover in osteoporosis 
TNF-α 
(Tumor necrosis factor-α) 
Potent inhibitor of bone collagen synthesis and stimulator of 
osteoclastic bone resorption, the net effect of which is to cause bone 
loss 
M-CSF 
(Macrophage Colony Stimulating 
Factor) 
Required for the formation of osteoclasts. Works with RANKL and 
TGF-β to cause the bone osteoclastic resorption. 
IL-6   
(Interleukin 1) 
A stimulator of bone formation. Stimulated and secreted by normal 
bone cells in response to PTH and 1,25(OH)2D3  
TGF-β 
(Transforming Growth Factor-β) 
Secreted by both osteoblasts and osteoclasts. Its action in bone 
remodeling is complex and is thought to be responsible for coupling 
bone formation to bone resorption. 
PTH  
(Parathyroid Hormone) 
Stimulates both bone formation and bone resorption. Its effects on 
bone formation are stimulated by Cbfa1 which also regulates 
RANKL expression and osteoclast formation. 
1,25(OH)2D3  
(1,25 Dihydroxyvitamin D) 
Indirectly stimulates the differentiation and fusion of osteoclast 
progenitors and also directly activates mature osteoclasts 
Calcitonin  An inhibitor of osteoclastic bone resorption activity. However, 
osteoclasts eventually escape from this inhibitory effect after 
continued exposure of calcitonin. 
Leukotrienes Have been related to osteoclastic bone resorption  
Thyroid hormone Stimulates osteoclastic bone resoprtion. Increased bone loss has been 
observed in patients with hyperthyroidism.  
2.2.4 Bone compartments 
The adult skeleton consists of cortical bone and trabecular bone with the proportion 
differing by anatomical regions. The proportion of cortical and trabecular bone does not 
change with age in the same way, which may explain the discrepancies in bone loss and 
fracture rates at different skeletal sites (32). 
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Cortical bone is dense or compact bone that comprises 85% of the total bone in 
the body and is the most abundant bone in the long bone shafts of the appendicular 
skeleton. The volume of cortical bone is regulated by the formation of bone on the 
periosteal surface and by resorption of bone on the endosteal surface. The periosteal 
formation increases the diameter of cortical bone and the endosteal resorption increases 
the thinning and porosity of cortical bone. In women, the loss of cortical bone occurs 
after the age of 40 and accelerates 5-10 years after menopause. This acceleration phase 
continues for 15 years and gradually slows down. Fragile cortical bone is a major 
predisposing factor for hip and wrist fractures (32). 
Trabecular bone comprises only 15% of the adult skeleton. Declines in trabecular 
bone may occur as early as 30 years of age, before the loss of cortical bone and is a major 
contributor to spine osteoporosis due to the high proportion of trabecular bone in 
vertebral bodies (32). The loss of trabecular bone results from not only thinning of the 
bone plates, but also by the complete perforation and fragmentation of trabeculae. 
Moreover, men and women appear to lose trabecular bone in different manners. In 
women, the loss of trabecular bone occurs by increased resorption with loss of trabecular 
numbers and connectivity, whereas it occurs by trabecular thinning in men (33). 
2.3 PATHOGENESIS OF OSTEOPOROSIS  
Osteoporosis results from a failure to achieve optimal peak bone mass in early adulthood 
and/or from a high rate of bone loss with aging. 
  24
2.3.1  Peak bone mass  
 Peak bone mass is the maximum bone density achieved at the end of the skeletal 
maturity. Peak bone mass is an important predictor of postmenopausal osteoporosis 
(34,35). Although peak bone mass is known to be achieved in early adulthood, both 
cross-sectional and longitudinal studies suggest that peak bone mass is achieved as early 
as late adolescence(36,37).  
Peak bone mass accrual during adolescence or early adulthood reflects an increase 
in bone size, which produces an increase in mineralized bone within the periosteal 
envelop (38). Bone size is determined mostly during the pubertal growth period. Growth 
velocity is high immediately after birth and it slows rapidly thereafter. At 12 months of 
age, the rate of bone growth starts to accelerate due to appendicular bone growth. 
Appendicular growth remains more rapid than axial growth velocity in the pre-pubertal 
years. At puberty, long bone growth slows down, but axial bone growth accelerates. 
Therefore, with the later onset of puberty, men appear to have longer bones than women. 
Sex differences in bone width are also established during puberty. Cortical width 
increases by periosteal bone formation in men, and by less periosteal bone formation but 
more endocortical apposition in women. Thus, compared with women, men have larger 
bones (longer and wider), which results in higher bone mineral content and aBMD, but 
not vBMD, compared with women. Trabecular vBMD increases by thickening of the 
trabecular plates. This increase seems to be similar in young men and women of the same 
ethnic origin. But men and women of different ethnicities do not have similar trabecular 
thickness. For example, African Americans have a higher trabecular volumetric BMD 
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due to their greater trabecular thickness. The trabecular thickness increases similarly by 
gender but differently by race during puberty (38). 
Peak bone density is highly heritable with heritability estimated as high as 
80%(39). Besides genetic contribution, there are many environmental factors that can 
affect bone mass accrual. The most important factors for peak bone mass accrual in 
adolescent and young adults include physical activity, nutrition (mostly calcium intake) 
and hormonal status. 
2.3.2 Age-related bone loss 
Age-related bone loss is a result of an imbalance in bone remodeling where bone 
formation does not replace all of the bone that is resorbed away by osteoclasts. Factors 
contributing to bone loss can be broadly categorized into hormonal, anthropometric, 
lifestyle and genetic factors.  
2.3.2.1 Hormonal factors 
Menopause affects bone mass in women due to the loss of estrogen. Estrogen reduces 
bone resorption by inhibiting osteoclast function. Estrogen loss after menopause results in 
more bone resorption than bone formation and thus leads to rapid bone loss. Recent 
studies also suggest an important role of endogenous estrogen and bone mass in men 
(40,41). For example, mutations in the gene encoding the aromatase gene, the enzyme 
responsible for converting androgens to estrogens, has been linked to low BMD in men 
(42). Androgens are also an important predisposing factor for osteoporosis in men. Men 
treated with androgen antagonists or gonadotropin releasing hormone agonists for 
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prostate cancer metastases experience rapid bone loss(43). Age-related hypogonadism is 
also thought to contribute to decreased BMD in men (44).  
Age-related changes in the growth hormone (GH)/insulin-like growth factor (IGF-
1) axis may also contribute to age-related bone loss (45). IGF-1 enhances the function of 
mature osteoblasts, increases bone matrix synthesis and prevents osteoblast apoptosis 
(45).  
Parathyroid hormone (PTH) and 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) are 
the principle regulators of calcium homeostasis. PTH stimulates the release of calcium 
and phosphate in bone and stimulates the reabsorption of calcium and inhibits the 
reabsorption of phosphate in kidney. Furthermore, PTH also enhances the synthesis of 
1,25(OH)2D3, which increases the intestinal absorption of calcium and phosphate. The 
interactions between PTH and 1,25(OH)2D3 maintain the blood calcium concentration. 
For example, a rise in blood calcium concentration decreases the secretion of PTH, while 
a decrease in blood calcium concentration increases the secretion of PTH. In addition, 
1,25(OH)2D3 and low phosphate increase blood calcium concentration thus inhibits PTH 
secretion. This regulation interaction is essential for the structural integrity of the 
skeleton (46). 
Interlukin-6 (IL-6) produced by osteoblasts, monocytes and T cells promotes 
osteoclast differentiation and activation and therefore plays a prominent role in post-
menopausal bone loss (47). Aging is associated with increasing levels of IL-6 and tumor 
necrosis factor-alpha (TNF-α). In bone, genetic variants in the IL-6 gene have been 
associated with IL-6 gene expression and bone resorption (48,49). TNF-α is a cytokine 
that enhances osteoclast formation by upregulating the stromal cell production of 
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RANKL and M-CSF (50,51). TNF-α not only stimulates osteoclast activity but also 
inhibits osteoblastogenesis (52). Therefore, the effect of TNF-α drives an imbalance 
between bone formation and bone resorption which may result in bone loss. 
2.3.2.2 Lifestyle and anthropometric factors 
Many lifestyle and anthropometric factors have been associated with bone density. It is 
important to thoroughly understand the roles of these factors in order to prevent or lower 
the risk of osteoporosis. The established risk factors for low BMD or osteoporosis 
include: low body weight, physical inactivity, cigarette smoking, excessive alcohol 
drinking, vitamin D deficiency, low calcium intake, use of glucocorticoids and certain 
medical conditions. The most common medical conditions contributing to low BMD are 
cystic fibrosis, muscular dystrophy, conditions that lower estrogen levels (eating 
disorders, excessive physical activity, ovarian failure of any cause, and menopause), 
endocrine disorders (diabetes, hyperparathyroidism, and Cushing’s syndrome), 
gastrointestinal diseases (celiac disease, intestinal malabsorption, primary biliary 
cirrhosis, and Crohn’s disease), blood disorders (hereditary anemias and multiple 
myeloma, leukemia), rheumatoid arthritis, lupus, and depression (53).   
2.3.2.3 Genetic factors 
Genetic factors also play an important role in the development of osteoporosis. Twin and 
family studies indicate that the heritability of aBMD ranges from 50% to 85% and that 
differences in heritability exist by gender and anatomical regions examined (11-13). 
Although most studies have examined the heritability of aBMD in Caucasians, men and 
women of Asian (54,55) and African (56) heritage also show high heritability of aBMD. 
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In contrast to the cross-sectional measures of aBMD, heritability for longitudinal aBMD 
change is less well defined. A twin study with 12 monozygotic (MZ) and 19 
dizygotic(DZ) twins showed that the intra-class correlation for lumber spine aBMD 
change was 0.93 among MZ twins and 0.51 among DZ twins, while another study (25 
MZ and 21 DZ) found that the heritability of aBMD change at the radius was 15% (57-
59). A more recent study of 388 premenopausal Caucasian women found a 38% and 35% 
heritability for change in area and aBMD at the femoral neck (60). Significant heritability 
of aBMD change was also reported in Mexican American families with heritability of 
39%, 46% and 45% at the hip, spine and radius, respectively (61). Moreover, studies 
have also suggested a strong genetic effect on the concentration of bone turnover markers 
(62-64). These findings also indirectly suggest that bone loss with aging is a heritable 
phenotype.  
Although population-based epidemiological studies suggest that family history of 
fractures is a risk factor for fractures and its association is independent of aBMD (65,66), 
results from heritability studies seem to be inconsistent. Some studies reported that 
susceptibility to fractures was not influenced by genetic factors (67), whereas others 
suggested that about 50% of the variation of fractures at the hip and wrist may be 
explained by  genetic factors (68,69). Environmental factors also play an important role 
in the occurrence of fractures and were often not considered in these studies.   
We have recently reviewed the genetic epidemiology of osteoporosis (70). The 
most widely studied candidate genes for aBMD and related phenotypes have been the 
vitamin D receptor (VDR), estrogen receptor alpha (ESR1), type I collagen (COLIA1), 
transforming growth factor-β (TGF-β), and the low-density-lipoprotein receptor related 
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protein-5 (LRP5) genes(70). The majority of these genetic association studies have 
focused on women and Caucasians.  
2.4 AREAL BMD IN MEN 
2.4.1 Assessment of aBMD 
Dual-energy X-ray absorptiometry (DXA) has been the most frequently used technique 
for assessing bone density and diagnosing osteoporosis in clinical and in research 
settings. DXA is a non-invasive technique with a very small radiation dose and excellent 
precision. The underlying concept of the DXA technology is that photon attenuation in 
vivo is a function of tissue composition. Rectilinear scanning of the supine body is 
performed and divides the body into a series of pixels, within each of which the photon 
attenuation is measured at two different energies. The DXA body composition 
measurement assumes that the body consists of three components that are distinguishable 
by X-ray attenuation properties: fat, bone mineral and fat-free or “lean” soft tissue (71). 
DXA is typically used to measure aBMD, bone mineral content (BMC) and cross-
sectional area (CSA) at the lumbar spine, whole body, forearm and hip in a two-
dimensional plane. The hip measurement is further subdivided into several regions such 
as femoral neck, trochanter, intertrochanter, and ward’s triangle.  
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2.4.2 Cross-sectional studies  
There are a few large-scale epidemiologic studies of aBMD and osteoporosis in men and 
most of them were conducted in Caucasians from different continents, such as Study of 
Osteoporotic Risk in Men (STORM, USA) (72), Rancho Bernardo Study (USA) (73), 
Osteoporortic Fractures in Men Study (MrOS, USA) (74), Rotterdam  Study 
(Netherlands) (2), TROST (Tromsø Osteoporosis Study, Norway) (75), DOES (Dubbo 
Osteoporosis Epidemiology Study, Australia) (76) and EVOS (European Vertebral 
Osteoporosis Study, Germany) (77). The mean aBMD value among Caucasian men aged 
55 and older is between 0.99 to 1.10 g/cm2 at the lumbar spine, 0.73 to 0.83 g/cm2 at the 
femoral neck and 0.88 to 0.99 g/cm2 at the total hip (78-81). In contrast to Caucasian 
men, men of other ethnicities have not been well represented in these osteoporosis-related 
studies. Studies of racial differences in aBMD have shown that African American men 
have 6-10% and 15-21% higher unadjusted and adjusted aBMD at the lumbar spine and 
femoral their Caucasian counterparts, respectively (82-84). We also demonstrated a 
higher hip aBMD in men of African descent compared to Caucasian men in the Tobago 
Bone Health Study (85,86). 
2.4.3 Longitudinal studies 
Although men have higher aBMD at all sites compared with women, men also experience 
significant aBMD decline with aging. In the Framingham study, Caucasian men aged 67-
90 had a significantly lower rate of decline in femoral neck aBMD but a similar rate of 
decline in forearm and lumbar spine aBMD, compared with women (3). In the Dubbo and 
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Rancho Bernardo studies, Caucasian men and women aged 60 or above had a similar rate 
of decline in hip aBMD (10,73). Table 2 summarizes the main results from several 
longitudinal studies of aBMD change with aging in older men. The mean annualized rates 
of decline in aBMD vary across different skeletal sites and studies. Theses discrepancies 
are likely due to, in part, different study designs, follow-up duration, assessments of 
aBMD, sample sizes, geographic areas, age distributions and other characteristics of the 
populations studied. However, the patterns of decline in aBMD with age are mostly 
consistent. Lumbar spine aBMD remained stable or increased with aging, whereas 
proximal femur aBMD decreased with aging in most studies listed in Table 2-2, with a 
larger decline observed at the femoral neck than the total hip. At the radius, especially at 
the shaft region, the rate of decline in aBMD appears to be much higher than at any other 
skeletal site. The higher rates of aBMD decline at the femoral neck and distal radius than 
lumbar spine may reflect differences in bone composition and/or falsely elevated lumbar 
spine aBMD due to spinal degenerative disease and osteophytosis which is know to 
interfere with DXA BMD measurements. Only one of these published studies described 
the magnitude of bone loss in men of African descent (87). This study found that African 
American men aged ≥65 had a lower rate of aBMD decline at the femoral neck and total 
hip than Caucasian men. However, our preliminary results comparing annualized aBMD 
decline rates between older Afro-Caribbean men from the Tobago Bone Health study and 
Caucasian and African American men from MrOS suggested that Afro-Caribbean men 
may experience a similar rate of aBMD decline compared with Caucasian and African 
American men (88). Moreover, no difference in aBMD decline rate was observed 
between Caucasian and African American men in the MrOS.  
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Table  2-2 Longitudinal studies of DXA aBMD changes with aging among older men 
Study/ Author Annualized rate of aBMD change Skeletal Site Age Population description 
Melton LJ, et al. (4) 
0.4%   
0.12% 
0.19% 
-0.19% 
0.03% 
-0.29% 
-1.69% 
-2.26% 
-0.48% 
-0.97% 
Spine 
 
Femoral Neck 
 
Total Hip 
 
Ultradistal Radius 
 
Midradius 
≥50 
≥70 
≥50 
≥70 
≥50 
≥70 
≥50 
≥70 
≥50 
≥70 
Sample size: 348 
Follow-up duration: 4 years 
Race/country: white, USA  
Rancho Bernardo (6) 
0.3%   
0.08% 
-0.17% 
-0.66% 
-0.39% 
-0.77% 
Spine 
 
Femoral Neck 
 
Total Hip 
 
65-74 
≥75 
65-74 
≥75 
65-74 
≥75 
Sample size: 297 
Follow-up duration: 4 years 
Race/country: white, USA 
MOST study (87) 
White: -2.1% 
Black: -1.12%  
White: -0.8%  
Black: 0.05%  
Femoral Neck 
 
Total Hip 
 
≥65 
Sample size: 349(white)/ 119(Black) 
Follow-up duration: 1.5 years 
Race/country: white/black, USA 
Framingham Study (3) 
-0.09%  
-0.38% 
-0.77% 
-0.90% 
Spine 
Femoral Neck 
Ultradistal Radius 
Radial Shaft 
67-90 
Sample size: 278 
Follow-up duration: 4 years 
Race/country: white, USA  
MrOS(88) 
White: -0.35% 
Black: -0.40% 
White: -0.37% 
Black: -0.44%  
Femoral Neck 
 
Total Hip 
≥65 
Sample size: 3585(white)/ 133(Black) 
Follow-up duration: 4.6 years 
Race/country: white/black, USA 
Warming L et al. (81) 
0.4% (over 2 yrs) 
-0.7% 
-0.6% 
Spine 
Femoral Neck 
Total Hip 
≥50 
Sample size: 96 
Follow-up duration: 2 years 
Race/country: white, Denmark 
TROST study (9) -0.48%  -0.39% 
Distal Forearm 
Ultradistal 
Forearm 
45-84 
Sample size: 2197 
Follow-up duration: 5 years 
Race/country: white, Norway 
EPIC study (5) -0.17%  Total Hip 65-74 
Sample size: 470 
Follow-up duration: 3 years 
Race/country: white, UK 
Dennison et.al. (8) 
0.19%  
0.64% 
0.22% 
-0.31% 
-0.30% 
-0.06% 
-0.31% 
-0.10% 
0.23% 
Spine 
 
 
Femoral Neck 
 
 
Total Hip 
60-64 
65-69 
70-74 
60-64 
65-69 
70-74 
60-64 
65-69 
70-74 
Sample size: 173 
Follow-up duration: 4 years 
Race/country: white, UK 
DOES study (10) 0.56%   -0.85% 
Spine 
Femoral Neck ≥60 
Sample size: 241 
Follow-up duration: 2.5 years 
Race/country: white, Australia   
Rotterdam Study (2) -0.28 % Femoral Neck ≥55 
Sample size: 1856 
Follow-up duration: 2 years 
Race/country: white, Netherland 
Tobago Bone Health 
Study (88) 
-0.62%  
-0.53% 
Femoral Neck 
Total Hip ≥65 
Sample size: 318 
Follow-up duration: 4.2 years 
Race/country: black, Tobago 
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2.4.4 Areal BMD and Fracture 
aBMD has been shown to be a strong predictor of fracture risk in women (14). The age-
adjusted relative risk of fractures increases by 1.5 to 2.5 fold with each standard deviation 
decrease (SD) in aBMD (89,90). Although there are relatively fewer studies relating 
aBMD to fractures in men, the findings still support a strong inverse association between 
aBMD and risk of fracture. For example, in the Rotterdam study, the age-adjusted 
relative risk of hip fractures increased by 3-fold with every 1 SD decrease in femoral 
neck BMD among Caucasian men aged 55 years and older (91).  In addition, the risk of 
fractures decreased from 30% to 65% at the hip, ankle, vertebrae and rib with every 1 SD 
increase in femoral neck aBMD (76). These results suggest that low BMD is an important 
determinant of osteoporotic fractures risk in men. However, the relationship between 
aBMD and fracture risk in men of African descent is less well defined. 
2.4.5 Correlates of areal BMD and accelerated bone loss 
Identifying risk factors for low aBMD or accelerated aBMD loss is important for the 
prevention of osteoporosis and osteoporotic fractures. Advanced age and low body 
weight have been well-established as risk factors in male osteoporosis; however, other 
factors such as smoking and physical inactivity have yielded inconsistent results. The 
conflicting findings may, in part, reflect the different methods used to collect information 
on lifestyle factors or different sample sizes.  
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2.4.5.1 Age 
Advanced age is one of the most important risk factors associated with low aBMD in 
men. Age is known to be inversely correlated with aBMD at most skeletal sites. The 
correlation between age and spine aBMD is less consistent (83,92,93). Unlike other 
skeletal sites, spine aBMD seems to increase with age. This association most likely 
reflects the confounding effect of osteoarthritis and calcification of the aorta (94). In the 
third NHANES survey, by age 80-85, Caucasian men lost approximately 25% of their 
femoral neck aBMD measured in the 20s (20). In the MrOS, every 5 year increase in age 
was associated with a 2-3% decrease in hip BMD and 0.7-1.6% increase in spine aBMD 
(79,80). In the longitudinal studies, the rate of decline in hip aBMD is significant in men 
(2-4,6,10,76) and is slower in men than in women (2-4,8,9,81). Although the relationship 
between age and longitudinal aBMD change in elder men and women of African heritage 
is less well defined, one study showed that the rate of hip aBMD decline accelerated with 
age among African American and Caucasian women after the age of 75 (African 
Americans: from -0.16% to -0.70% per year (Caucasians: from -0.43% to -0.87% per 
year) (95).           
2.4.5.2 Body weight and weight change 
Body weight is one of the strongest correlates of aBMD in men and women. A positive 
association between body weight (or body mass index, BMI) and aBMD among middle-
aged and elderly men has been well documented for both Caucasians and African 
Americans in cross-sectional studies (72,78,83,92,93,96). The variation in body weight 
may account for 10% to 17% of the total variation in aBMD at the lumber spine and 
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femoral neck (10). Body fat and lean mass, the major components of body weight, are 
also known to be related to aBMD in Caucasian and Afro-Caribbean men (78,97,98).    
Weight loss with aging is common among the elderly and has an important impact 
on skeletal health. In the Rancho Bernardo study, weight change was an important 
correlate of bone loss. For example, men who lost 2kg or more of their body weight had a 
significantly lower hip aBMD than those who gained more than 2kg of their weight (92). 
In addition, weight losers were twice as likely as others to lose at least 1% of their aBMD 
per year (73). Lower initial BMI was also significantly associated with greater bone loss 
than higher BMI (2,6,8). In the Framingham, Rancho Bernardo, MrOS and EPIC studies, 
men who lost 5% of their baseline weight had a significantly greater rate of aBMD 
decline at the lumbar spine, hip and radius than those who gained 5% of their baseline 
weight (3,5-7). However, the relationship between weight loss and aBMD change has not 
yet been established in men of African heritage. 
2.4.5.3 Physical activity and muscle strength 
The skeleton responds to weight-bearing activity by increasing new bone formation and 
altering the distribution of bone mass to accommodate the mechanical forces applied to it 
(99). The forces applied to bone from daily activities and exercise are therefore important 
for normal development and maintenance of bone mass and strength (100). The effect of 
exercise on aBMD or bone loss in men is not well defined. A greater current or historical 
physical activity level has been associated with higher aBMD in middle-aged and elderly 
men (72,80,92).  Men engaged in regular exercise also had a higher aBMD at the spine, 
total hip and femoral neck (6,80). However, some studies found no significant association 
between exercise and aBMD in men (79). The positive effects of exercise on aBMD are 
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likely due to the beneficial effects of exercise on muscle strength (10). Muscle strength, 
often defined by grip strength, has been associated with higher aBMD in several studies 
of male skeletal health (72,76,80). The impact of physical activity on age-related aBMD 
decline in men is not well characterized. Men engaged in intense activity had a slower 
aBMD decline rate than those that did not engage in intense activity (59). Disability is 
sometimes used as an indirect surrogate of physical inactivity. In the Rotterdam study, 
men with lower limb disability had a greater decline in aBMD than those without 
disability (2). Association between physical activity and bone loss in men has been 
primarily examined in Caucasians only. 
2.4.5.4 Cigarette Smoking 
Smoking is an established risk factor for osteoporosis. Animal studies suggest that 
exposure to nicotine impairs bone formation (101). Nicotine produces a dose- and time-
dependent reduction in DNA synthesis and cellular proliferation of osteoblast-like cells in 
vitro, suggesting that nicotine may have direct toxic effects on bone cells (102).  It has 
also been proposed that cigarette smoking may contribute to increased bone loss and low 
aBMD by accelerating normal age-related declines in androgenic hormone levels (103). 
Current smokers had a lower aBMD compared with non-smokers (92,104-106), although 
some studies showed no association between smoking and aBMD (72,79,80). In a meta-
analysis, male smokers had 0.3 SD lower femoral aBMD compared with nonsmokers and 
the effect size was similar to that observed among women (107). In the limited 
publications of longitudinal studies of aBMD changes in men, all in Caucasian men, 
smokers consistently had a greater aBMD decline rate at the hip compared to nonsmokers 
(2,3,6,73).   
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2.4.5.5 Alcohol drinking 
The mechanisms for alcohol-induced osteoporosis are not known, but evidence suggests 
that impaired osteoblastic activity with normal osteoclastic activity may contribute to 
reduced bone mass in alcoholic patients (108). Moderate alcohol consumption has been 
associated with a higher bone density in several (92,93,109), but not all (72,76) studies of 
middle-aged and elderly Caucasian men. However, the effect of moderate alcohol 
drinking on aBMD may also be mediated through other confounding factors such as age 
and weight (110). There have been few studies of alcohol consumption and rates of bone 
loss in men. Several of them found a positive but non-significant association between 
moderate alcohol consumption and the aBMD change in older Caucasian men 
(2,3,6,73,76). No longitudinal study of aBMD changes has examined the relationship 
between BMD changes and alcohol consumption in black men. 
2.4.5.6 Calcium intake 
Calcium is the major mineral component of bone. Calcium deficient diet has been linked 
to decreased bone calcium content. Adequate vitamin D is essential for optimal calcium 
absorption. An inadequate intake of either calcium or vitamin D results in a reduced 
calcium absorption and a slightly low blood concentration of ionized calcium. In 
response to this, blood PTH concentration increases and stimulates bone turnover (111). 
Calcium deficiency is the most common cause of increased bone resorption in older 
individuals likely due to low dietary intake, lack of sun exposure, malabsorption and 
anorexia (112). Population studies have not consistently linked higher dietary calcium 
intakes to higher bone density or reduced bone loss with aging in men. Positive 
association between aBMD and calcium intake was observed in some (2,72,79,92), but 
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not all studies (76,80). However, the effect of calcium on bone density might be site-
specific. In the Rancho Bernardo study, older men who consumed 800mg calcium per 
day had a greater aBMD at the lumbar spine, but not hip, compared to those whose 
calcium intake was under 800mg/day (92). Dietary calcium intake or calcium supplement 
use was not significantly correlated with aBMD change in older men in most of the 
longitudinal studies (5,6,73,76). The impact of calcium intake and vitamin D on aBMD 
and aBMD change with aging in men of African descent is unknown. However, studies 
have shown that African American women had significantly lower calcium intake and 
lower serum vitamin D levels compared to their white counterparts but still maintained a 
high level of aBMD (113).   
2.4.5.7 Medication 
Chronic use of several medications may reduce bone density and increase the risk of 
fractures. The use of glucocorticoids, thiazide diuretics, and thyroid hormone are among 
the most common and well-studied medications that have been known to be associated 
with low aBMD, aBMD decline and osteoporotic fractures. The effect of medication use 
on osteoporosis risk has not been confirmed in all population studies, most likely due to 
inadequate statistical power from the low frequency of use of these medications. 
Glucocorticoids, an anti-inflammatory and immunosuppressive medication, decrease 
bone mass by directly inhibiting osteoblastic function and formation, decreasing 
intestinal calcium absorption, and increasing urinary calcium excretion. Chronic use of 
corticosteroid is linked to secondary osteoporosis among men (114). However, studies 
found inconsistent effects of corticosteroids on aBMD. No significant association 
between corticosteroids use and hip aBMD was observed among men in the STORM 
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study (72), but a reversed association was observed in MrOS (80). Thiazide diuretics or 
thiazide-like diuretics, a common hypertension medication, decrease urinary calcium 
excretion and have been associated with increased aBMD in men in the cross-sectional 
studies (72,80,115,116). This effect also seemed to be site-specific (115). However, a 
longitudinal analysis from the same study showed no association between thiazide 
diuretics use and aBMD change (6). Thyroid hormone is used chronically to treat 
hypothyroidism. Use of thyroid hormone has been associated with reduced aBMD in 
women (117). Due to the less common use of thyroid hormone among men, information 
regarding the impact of thyroid hormone use on aBMD in men is limited. One study 
found that men who reported an average of 15.5 years use of thyroid hormone had similar 
levels of aBMD at multiple skeletal regions as nonusers (118). 
Androgen deprivation therapy (ADT) is used to prevent the recurrence of prostate 
cancer after radical prostatectomy or radiation therapy. While it suppresses tumor growth, 
ADT also decreases aBMD (43). Androgens help to maintain the balance between bone 
synthesis and degradation, but decrease bone resorption via the aromatization of 
testosterone to estrogen. ADT disrupts this normal hormonal balance required for bone 
health (119). In the MrOS study, prostate cancer was associated with low spine but not 
hip BMD (80), whereas a higher hip aBMD was observed among men with prostate 
cancer in Afro-Caribbean population from the Tobago prostate cancer survey study (120). 
Another study also showed that men with prostate cancer may experience significant 
bone loss due to the nature of the disease even before undergoing ADT (121). To our 
knowledge, no study has reported the relationship between aBMD and use of 
glucocorticords, thiazide diuretics, thyroid hormone and ADT in men of African descent. 
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Although the Tobago study has reported the relationship between aBMD and prostate 
cancer, the effect of prostate cancer treatment was not evaluated (120).  
2.4.5.8 Medical conditions 
Several medical conditions have been associated with aBMD in men. Secondary causes 
of osteoporosis include excessive use of glucocorticoids or other immunosuppressive 
drugs, hypogonadism, chronic obstructive pulmonary disease and asthma, cystic fibrosis, 
gastrointestinal disease, hypercalciuria and hyperparathyroidism, and immobilization 
(122). Besides these secondary causes of osteoporosis, type II diabetes has also been 
related to increased aBMD independent of body weight in some (123-125), but not all 
(126,127) studies. Recent longitudinal studies have shown an increased risk of hip 
fractures associated with type II diabetes (128). In the Health, Aging, Body Composition 
(Health ABC) study, both Caucasian and African American men and women with type II 
diabetes had a significantly higher aBMD at the femoral neck and total hip compared 
with those with normal glucose homeostasis. However, association between diabetes and 
bone loss was only observed in women, but not in men (129). 
2.5 VOLUMETRIC BMD IN MEN 
2.5.1 Assessment of vBMD 
Quantitative computed tomography (QCT) is an established technique for measuring 
BMD in the axial spine and peripheral skeleton. In contrast to DXA measures of aBMD, 
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QCT provides a three-dimensional measure of volumetric that is not confounded by 
differences in bone size. In addition, QCT has the ability to distinguish trabecular and 
cortical bone. Compared with DXA, QCT is more sensitive to detecting bone loss 
because it selectively measures changes in the more metabolically active trabecular bone 
compartment. 
Peripheral QCT (pQCT) scanners have been employed for measuring the bone 
mineral content and volumetric density of the appedicular skeleton in pediatrics because 
of the lower radiation exposure than QCT. It also provides different skeletal quality 
measures besides density for trabecular and cortical bone. The ultra-distal and shaft 
regions of the radius and tibia are the common scanning sites for pQCT due to the 
different amounts of trabecular and cortical bone in these regions. The ultra-distal 
scanning site contains up to 80% of trabecular bone and is used for the examination of the 
trabecular compartment. The shaft region contains approximately 90% of cortical bone. 
The bone mineral content remains fairly constant between 10% to 90% of the radius 
length, making this site preferable for measuring cortical properties (130).   
2.5.2 Results from cross-sectional and longitudinal studies 
Population studies of vBMD have been predominantly conducted in women. There are 
few studies in men and most of them have focused on young males. There are also 
limited data on the epidemiology of vBMD in men of African heritage. 
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2.5.2.1 Cortical vBMD 
Greater cortical bone density in Caucasian men compared with women is observed in 
several cross-sectional studies (131-133). However, Riggs et al. have recently found that 
young women aged 20 to 29 had about 10% higher cortical vBMD at the femoral neck, 
radius and tibia than men at the same age (134). This association was reversed when 
comparing men and women aged 70 to 97 years old (135).  A study by Sigurdsson et al. 
also reported similar cortical vBMD between elderly men and women (136).  
Age-related decrease in cortical vBMD occurs in both genders. In Caucasian men, 
cortical vBMD at the femoral neck, radius and tibia decreased with age (131,134). 
Studies reported that cortical vBMD decreased slowly over the entire life span in Italian 
men (131), but decreased significantly greater after middle age in American men (134). 
Very few studies have measured vBMD by QCT or pQCT among men of African 
descent. Taaffe et al. compared vBMD at the femoral shaft, predominantly cortical bone, 
and found no significant differences in vBMD between Caucasian and African American 
men aged 70-79 (133).  
2.5.2.2 Trabecular vBMD 
Studies have shown a greater trabecular vBMD in Caucasian men than women at the tibia 
and radius (131,132,134) and hip(136). However, gender differences in trabecular vBMD 
at the lumbar spine have not been consistent (134,136,137). Therefore, the gender 
differences in trabecular vBMD may be site-dependent. The decrease in trabecular 
vBMD seems to occur in a linear fashion starting as early as 30 years of age for both men 
and women (131,134,138,139). There is a more profound decrease in trabecular vBMD 
with age at the central (50%) than peripheral (25%) skeletal sites (134).  
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2.5.3 Volumetric BMD and fracture 
Few studies have examined pQCT or QCT measures of vBMD and its relationship with 
fractures. For both men and women, those with vertebral fracture had a lower total, 
cortical and trabecular vBMD compared to controls (132). A study by Jamal et al. 
showed that every one SD decrease in cortical, but not trabecular, vBMD at the radius 
was associated with a 16-fold risk of fractures among 52 hemodialysis patients after 
adjusting for age, weight and sex (140). The relationship between vBMD and fractures in 
men of African descent has not been established. 
2.5.3.1 Correlates of volumetric BMD 
Unlike aBMD, there are very few studies on the correlates of vBMD in men. In some 
studies, a higher level of exercise was not associated with cortical vBMD (141-143). On 
the other hand, exercise seemed to be associated with higher trabecular vBMD (142). 
Several studies showed that physically active men have a higher trabecular vBMD than 
sedentary men (141,142,144). Grip strength was also found to be positively correlated to 
cortical and trabecular vBMD (132,145). Smoking is known to have a negative effect on 
aBMD; however, what we knew about effect of smoking on vBMD was limited. In the 
GOOD study, there was no difference in cortical vBMD between male smokers and 
nonsmokers(106), where Kaji et al. also found similar cortical and trabecular vBMD in 
male smokers compared with non-smokers (132). 
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2.6 GENETICS OF OSTEOPOROSIS 
2.6.1 Importance of genetics in osteoporosis 
We have known for several decades that genetic factors and their interaction with 
environmental factors have a major impact on bone mineral density and the risk of 
developing osteoporosis in men and women. Understanding the genetic effects on bone 
density may have a major impact on the diagnosis, treatment, and prevention of 
osteoporosis. Research has clearly confirmed a strong genetic contribution to BMD. 
However, the genes and allelic variants conferring susceptibility to this condition have 
only more recently begun to be identified.  
2.6.2 Candidate gene studies of osteoporosis 
Several strategies are used to identify the genetic factors contributing to osteoporosis 
related phenotypes such as genome-wide linkage mapping in families, genome-wide 
linkage disequilibrium (LD) mapping, and candidate gene association studies. In brief, 
genome-wide linkage mapping follows the segregation of chromosomal regions marked 
by genetic variants in families in the search for regions of the genome that co-segregate 
with the disease or phenotype. This approach has great potential to identify genes or 
protein products with previously unknown function. For example, low density lipoprotein 
receptor-relate protein 5 (LRP5), a co-receptor for the wingless-type family of growth 
factor, was showed to segregate with a high aBMD phenotype and its function on bone 
metabolism was unknown until its discovery using the genome-wide linkage mapping 
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approach. Genome-wide LD mapping with single nucleotide polymorphisms (SNPs) in 
unrelated individuals has also been proposed to localize osteoporosis susceptibility genes. 
This approach tests for differences in allele frequencies between cases and controls or 
tests for differences in mean values of bone related phenotypes (e.g., BMD) across 
genotypes on a genome-wide basis. Candidate gene association studies rely on traditional 
epidemiologic study designs to identify the relationship between alleles and/or genotypes 
and phenotype. Using this approach, candidate genes are identified first according to their 
established biological role in bone metabolism. Then, epidemiologic methods are used to 
test whether the genotype(s) is/are associated with phenotypes. Although several 
candidate genes for osteoporosis have been investigated to date, studies often yielded 
inconsistent or inconclusive results due to differences in the populations being studied or 
study design.  The most widely studied candidate genes have been the vitamin D receptor 
(VDR), estrogen receptor alpha (ESR1), type I collagen (COL1A1), and   Transforming 
Growth Factor-β (TFG- β) genes (70). 
Most of the genetic studies of osteoporosis in humans have examined DXA 
measures of aBMD. However, studies have shown that vBMD measured by QCT and 
pQCT also has a high heritability. Lenchik et al. found that the heritability for vBMD at 
the lumbar spine was 73% (146). In the Tobago Family Study, the estimated heritability 
of cortical vBMD was 29% at the radius and 42% at the tibia, whereas the heritability of 
trabecular vBMD was 70% at both the tibia and radius. In this study, the heritability of 
trabecular vBMD was also higher than the heritability observed in aBMD at the whole 
body, lumbar spine, total hip and femoral neck(56).  
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Some recent candidate gene association studies have examined vBMD by pQCT 
as the phenotype. For example, Lorentzon and colleagues examined the association of 
polymorphisms in aromatase (CYP19), the key enzyme in the conversion of testosterone 
to estradiol, with both aBMD and vBMD in young adult males aged 18 to 20. They 
reported that a CYP19 polymorphism was independently associated with aBMD of the 
radius, lumbar spine, and total body. Trabecular vBMD was not associated with CYP19 
polymorphisms at the radius and tibia, whereas cortical vBMD was significantly 
associated with CYP19 polymorphisms at the radius only (42). The same research team 
also investigated the association of a functional polymorphism in the catechol-O-
methyltransferase (COMT) gene, involved in the degradation of estrogens, and vBMD in 
young adult males (147). This polymorphism was found to associated with trabecular and 
cortical vBMD at the radius(147). 
There have been few other candidate gene association studies of QCT measures of 
vBMD and very limited data on the genetic association of vBMD in men or women of 
African heritage. In the proposed dissertation project, we will focus our attention on a 
newly discovered candidate gene for vBMD: the ectonucleotide pyrophosphatase 
/phosphodiesterase 1 (ENPP1) gene (148). 
2.6.3 Ectonucleotide pyrophosphatase / phosphodiesterase 1 (ENPP1) 
The transmembrane glycoprotein, ENPP1, also known as plasma-cell membrane 
glycoprotein 1 (PC-1), plays an important role in skeletal mineralization. The initial 
stages of mineralization begin in chondrocyte- and osteoblast-derived matrix vesicles 
(MVs) which contain calcium and inorganic phosphate ions (Pi). Crystals of 
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hydroxyapatite are formed within the MVs in growth plate cartilage and developing bone. 
Crystals of hydroxyapatite grow through the MV membrane to the extracelluar 
environment. Exposure of the hydroxyapatite crystals to the extracelluar milieu further 
enables growth and proliferation of the crystals. Inorganic pyrophosphate (PPi) inhibits 
the ability of Pi to crystallize with calcium to form hydroxyapatite and thereby suppresses 
hydroxyapatite deposition. Therefore, the balance between levels of Pi and PPi is crucial 
for normal mineralization to proceed (149).  
The following figure showed the biological pathway of ENPP1 gene. Tissue-
nonspecific alkaline phosphatase (TNAP), nucleotide pyrophosphatase phosphodiesterase 
1 (NPP1) and multiple-pass transmembrane protein ANK are three important molecules 
identified as central regulators of extracelluar PPi and Pi levels. TNAP, encoded by the 
Akp2 gene, plays an important role in bone matrix mineralization by hydrolyzing PPi, 
whereas NPP1, encoded by ENPP1, regulates mineralization by generating PPi. The 
transmembrane protein, ANK, acts as a transport channel for PPi and therefore has a 
similar function to NPP1 in increasing extracelluar PPi levels (149).  
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Figure  2-1 Biological pathway of bone mineralization 
 
TNAP is an important promoter of mineralization because it catalyzes the 
hydrolysis of PPi thereby decreasing the concentration of this calcification inhibitor, 
while concomitantly increasing Pi levels. Mice with a deletion of the Akp2 gene (Akp-/-) 
develop severe hypophsphatasia, a disease characterized by rickets, osteomalacia, 
spontaneous bone fracture and increased PPi levels. In contrast, NPP1 serves as a 
physiological inhibitor of calcification by generating PPi. In human infants, severe NPP1 
deficiency was found to be associated with a syndrome of spontaneous infantile arterial 
and periarticular calcification (150,151). ENPP1 knockout mice show decreased levels of 
PPi and mineralization abnormalities that include osteoarthiritis and ossification of the 
posterior longitudinal ligament of the spine. Studies by Suk et al found evidence for 
association between ENPP1 gene variation and osteoarthiritis in Russian population 
(152).  
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Yerges et al. have recently identified that an intronic tagging SNP in ENPP1 is 
significantly associated with vBMD at the femoral shaft using QCT in older Caucasian 
men (148). We will test if tagging SNPs in ENPP1 are associated with DXA measures of 
aBMD, rates of decline in BMD, and pQCT measures of vBMD in men of African 
descent in the current project. 
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2.7 LIMITATIONS OF THE EXISTING LITERATURE 
Osteoporosis studies have historically been conducted in Caucasian women due to the 
higher prevalence of this skeletal condition in this population group. However, in more 
recent years there has been an increased awareness of the importance of male 
osteoporosis. Longitudinal studies of bone loss with aging in men are still lacking, 
especially in regard to the risk factors for accelerated bone loss. Although bone density 
measured by DXA (areal BMD) has been widely used to diagnose osteoporosis, this 
measure is known to be confounded by bone size, where higher areal BMD may reflect 
bigger bone size, not necessarily higher bone density. Few population studies have used 
QCT or pQCT to characterize the correlates of volumetric BMD. In addition, there has 
been no study, to our knowledge, that thoroughly examines the potential anthropometric, 
medical, and lifestyle factors that may be associated with volumetric BMD.  As with 
environmental factors, very few genetic association studies have assessed QCT or pQCT 
measures of bone related phenotypes.  
Non-white populations have also been largely under-represented in 
epidemiological studies of osteoporosis, particularly in men.  It is important to better 
understand and confirm the potential genetic and environmental factors that are 
associated with bone density and changes in bone density with aging using advanced 
techniques like pQCT in non-white populations. 
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2.8 SPECIFIC AIMS 
The aim of Research Article 1 was to better understand the age-related patterns and 
determinants of hip BMD changes (total hip and femoral neck) in men of African 
descent. We evaluated the magnitude of age-related changes in hip BMD across age and 
the effect of weight change on hip bone loss. We then assessed how changes in hip BMD 
correlate with demographic characteristics, anthropometric and body composition 
measures, lifestyle factors and medical history. 
The aim of Research Article 2 was to better understand the age-related patterns in 
trabecular and cortical vBMD at the radius and tibia among men of African heritage.  We 
also sought to identify the correlates of vBMD, including demographic characteristics, 
anthropometric and body composition measures, lifestyle factors, dietary intake, medical 
history, and medication, related to trabecular and cortical vBMD at the radius and tibia, 
respectively. 
The aim of Research Article 3 was to examine single nucleotide polymorphism 
associations in the ENPP1 gene and BMD measurements, including rate of decline in 
aBMD and aBMD at the total hip and femoral neck, and trabecular and cortical vBMD at 
the radius and tibia, in men of African descent. 
We used longitudinal and cross-sectional data from the Tobago Bone Health 
study to perform analyses for these three research articles. The Tobago Bone Health 
study is a large scale population study of Afro-Caribbean men aged 40 and older on the 
island of Tobago.   
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3.1 ABSTRACT 
Very little is known about the magnitude, pattern and determinants of bone loss with 
advancing age among men, particularly among those of African descent. We examined 
the rate of decline in hip bone mineral density (BMD) and indentified potential factors 
associated with an accelerated loss of BMD among 1,691 men of African ancestry aged 
≥40 years. BMD at the proximal femur was measured at study entry and after an average 
of 4.4 years by dual-energy X-ray absorptiometry. The overall rate of decline in femoral 
neck BMD was 0.29±0.81%/yr in the total sample (p<0.0001). However, a U-shaped 
relationship between advancing age and the rate of decline in BMD was observed. For 
example, the rate of decline at the femoral neck was -0.38±0.77%/yr among men aged 
40-44 years (P<0.0001), decelerated to -0.15±0.81%/yr among men aged 50-54 yrs 
(P=0.0026) and then accelerated to -0.52±0.90%/yr among those aged 75+ yrs 
(P<0.0001). Men who lost ≥5% of their initial body weight during follow-up had a 
significantly greater rate of decline in BMD than those who remained weight stable or 
gained weight (p<0.0001). The relationship between weight loss and bone loss was more 
pronounced among men who were older and leaner at study entry (P<0.03 for 
interactions). We also observed a strong impact of advanced prostate cancer and its 
treatment with androgen deprivation on the rate of decline in BMD. Men of African 
ancestry experience substantial bone loss with advancing age that appears to be 
comparable to the rate of loss among Caucasian men in other longitudinal studies. 
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Additional studies are needed to better define the natural history and factors underlying 
bone loss with aging in men of African ancestry. 
3.2 INTRODUCTION 
Although osteoporosis is more prevalent among women than men, men also experience 
substantial bone loss and an increase in fracture incidence with advancing age. However, 
little information exists about the natural history, magnitude and correlates of bone loss 
with aging among men, especially among men of African ancestry. Osteoporosis is a 
global public health problem and as the population ages more men throughout the world 
will develop osteoporosis and its associated fractures, including men of African 
ancestry(1). The lower prevalence of osteoporosis in men of African ancestry compared 
with other ethnic and racial groups has led to the belief that osteoporosis represents less 
of a problem in this population.  However, the African ancestry population is expected to 
comprise a growing proportion of the incidence and economic burden of osteoporosis-
related fractures over the next 20-50 years in both the U.S. (2) and world-wide (1). These 
demographic trends underscore the importance of better understanding the natural history 
and determinants of bone loss and osteoporosis in men of all ages and racial/ethnic 
background.  
Most longitudinal studies of bone mineral density (BMD) changes with aging in 
men have been conducted among Caucasian men in North America (3-8), Europe (9-11) 
and Australia (12). These studies have identified body weight and changes in body 
weight as the major correlates of bone loss with aging in men. Smoking has also been 
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reported as a potential risk factor for bone loss in some studies (3,4,7,13,14), whereas 
other lifestyle factors such as alcohol consumption, calcium intake and physical activity 
have been inconsistently related to bone loss (3,4,7,12). To our knowledge, only a single 
study has characterized the magnitude and correlates of bone loss in men of African 
descent (14). In this study, older age, lower initial body weight and smoking were 
correlated with a greater decline in BMD among 119 African American men aged ≥65 
years. The aim of the present study was to examine further the magnitude, age-related 
patterns and correlates of the decline in hip BMD with aging in a large cohort of middle-
aged and elderly men of African ancestry. 
3.3 METHODS 
3.3.1 Study population 
The population-based Tobago Bone Health Study was first conducted on the Caribbean 
island of Tobago in 2000 as described previously (15,16). In brief, recruitment was 
accomplished by word of mouth, hospital flyers and radio broadcasting. To be eligible, 
men had to be 40 years and older, ambulatory and not terminally ill. Questionnaires were 
administered to obtain information on demographic characteristics, occupation, medical 
history, and lifestyle related factors. A total of 2,652 men completed an initial dual-
energy x-ray aborptiometry (DXA) scan for assessment of BMD and body composition at 
that visit. The self-reported ethnicity of the cohort is 97% African, 2% East Indian, <1% 
white, and <1% "other".  
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In late 2004, participants were re-contacted for a second DXA scan to assess the 
rate of change in BMD. A total of 1,748 men (70% of survivors) returned for the follow-
up exam. We excluded 36 men who identified themselves with ethnicity other than Afro-
Caribbean and 21 men who had incomplete data. We also subsequently excluded 233 
men with prostate cancer and/or history of androgen deprivation therapy for prostate 
cancer from analysis because of their strong influence on BMD in this population. 
The final study sample for the present analysis was 1,458 men. The Institutional Review 
Boards of the University of Pittsburgh and the Tobago Ministry of Health and Social 
Services approved this study and all participants provided written informed consent 
before data collection.   
3.3.2 Densitometry 
BMD was measured at the proximal femur and sub-regions at both the baseline and 
follow-up visits using a single Hologic QDR 4500W densitometer (Hologic, Inc., 
Bedford, MA). The left hip was scanned unless the participant had a fracture or a total hip 
replacement. Trained and certified technicians performed the DXA scans and followed a 
strict protocol for both visits. Longitudinal machine stability was assessed from plots of 
daily spine phantom scans, and reviewed monthly. A weekly print out of QC plots was 
generated to detect short-term inconsistencies and long-term drift. The scanner was stable 
throughout the course of the study.  
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3.3.3 Anthropometric and body composition assessments 
Body weight was measured in kilograms with participants wearing light clothing and 
without shoes, using a calibrated balance beam scale at both visits. Height was measured 
in centimeters without shoes, using a wall-mounted height board. Whole body fat and 
lean mass were also measured using DXA. Left and right grip strength was measured 
with a hand-grip dynamometer as a surrogate for upper body and overall strength 
(Preston Grip Dynamometer, JA Preston 136 Crop.). Average grip strength was based on 
two repeated measurements from left and right hands. 
3.3.4 Other measurements 
Questionnaires were administered by trained interviewers and nurses to obtain 
information on demographic characteristics, lifestyle factors as well as medical history. 
In the current analysis, we used information from the baseline exam to assess potential 
factors related to the subsequent rate of decline in BMD. Mixed African ancestry was 
defined by self-report of one to three African-descent grandparents. Other factors that 
were assessed included history of cigarette smoking, alcohol consumption, time spent 
watching television, time spent walking, medical history of facture, hypertension, 
coronary heart disease (CHD), stroke, diabetes, chronic bronchitis, and arthritis. We also 
asked participants to rate their overall health status compared to others of their age. 
Diagnosis of prostate cancer, advanced prostate cancer (prostate specific antigen>40 or 
Gleason score >7), and androgen deprivation therapy (ADT, use of Leuprorelin or 
orchiectomy) were also recorded at baseline. 
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3.3.5 Statistical Analysis 
The annualized rate of change in BMD during follow-up was calculated as the percent 
BMD change from baseline to follow-up divided by duration in years between the two 
scans. Percent change in body weight or body composition was calculated as the 
difference between baseline and follow-up measures divided by baseline measures and 
multiplied by 100. We also categorized percent weight change into 3 groups: weight gain 
(>5% weight gain), weight stable (weight change between -5% and 5%) and weight loss 
(>5% weight loss). 
We first compared the baseline characteristics between men who did and did not 
return for the follow-up visit, regardless of their race and ethnicity, using analysis of 
covariance (ANCOVA) for continuous variables with age adjustment and Chi-square 
tests for dichotomous variables. Analysis of variance (ANOVA) and ANCOVA were 
used to evaluate the annualized percentage rate of change in BMD across different age 
categories (e.g. 5-year age groups or greater than 55 years) and across weight change 
groups. We evaluated the age-adjusted and age- and weight-adjusted contribution of each 
individual variable to the annualized rate of change in BMD by using linear regression 
analysis. The strength of the association is expressed as an absolute difference in units of 
change chosen to approximate one standard deviation (SD) in the distribution for each 
continuous variable or null category for dichotomous variables. The formula used to 
calculate the absolute difference in rate of change in BMD per unit change (SD) of the 
independent variable was: (β)= ((unstandardized β x unit change in independent 
variable). The corresponding 95% confidence intervals were calculated using the 
following formula: (((β x ±1.96 x standard error) x unit change). We also evaluated the 
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interactions between weight change and age as well weight change and BMI on the rate 
of BMD decline using ANCOVA.  
Multiple linear regression analysis was performed using a stepwise procedure to 
determine the potential independent correlates of the annualized rate of change in BMD. 
Variables from the age- and weight- adjusted univariate model with a P value <0.10 were 
further entered in the multiple linear regression model. Age was forced into all models. 
We assessed multi-collinearity by inspecting the variance inflation factor (VIF). Due to 
the high correlation of body weight with lean and fat mass, we developed two different 
multiple linear regression models: 1) models with body weight only; and 2) models 
substituting fat and lean mass for body weight. Statistical analyses were performed using 
the Statistical Analysis System (SAS, version 9.1; SAS Institute, Cary, NC).  
3.4 RESULTS 
Table 1 shows the baseline characteristics of men who did and did not attend the follow-
up exam. As expected, men who did not return were older, weighed less, and had lower 
baseline BMI than those who participated in the follow-up exam. Non-participants also 
were more likely to smoke, report poorer health status and have a greater prevalence of 
hypertension, heart disease, diabetes and arthritis. Non-participants also had significantly 
lower hip BMD than participants at the baseline exam.  
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3.4.1 Rate of change in BMD and androgen deprivation 
The average length of time between DXA scans was 4.4±0.8 years (range, 1.1 to 6.9 
years). Men with advanced prostate cancer and men who had a history of androgen 
deprivation therapy for prostate cancer had a significantly greater rate of decline in BMD 
compared to their counterparts.  For example, the average rate of decline in BMD was to 
0.137±0.588 %/yr at the total hip and 0.333±0.841 %/yr at the femoral neck (data not 
shown) for all men. The rate of decline in BMD was 0.78%/yr greater at the total hip and 
0.58%/yr greater at the femoral neck for men with advanced prostate cancer (prevalence, 
2%) compared to men without prostate cancer (both, p<0.0001). Men with non-advanced 
prostate cancer (prevalence, 11%) had a 0.08% greater (p=0.08) annualized rate of 
decline in BMD at the total hip and 0.15% greater (p=0.02) at the femoral neck, 
compared to men without prostate cancer. Approximately 6% of the study population 
reported that they had either taken Leuprorelin or underwent orchiectomy for prostate 
cancer. Men on either of these treatments experienced an approximately 0.4%/yr greater 
(p<0.0001) rate of decline in total hip and femoral neck BMD compared to men who had 
neither of these treatments. Because prostate cancer and its treatment by androgen 
deprivation had a strong impact on the rate of decline in BMD, we excluded the 233 men 
with prostate cancer or who had undergone androgen deprivation from subsequent 
analyses. 
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3.4.2 Rate of change in BMD and age group 
Total hip and femoral neck BMD declined by 0.10±0.55%/yr and 0.29±0.81%/yr among 
the men who did not have prostate cancer or who had undergone ADT (p<0.0001 for 
both). To examine the age-related patterns in the rate of decline in BMD among these 
men, we stratified the total sample by 5 year age groups using age at study entry (Figure 
1). The rate of decline in BMD across age groups appeared to have a U-shape 
relationship. Men aged 40-44 years had a significantly greater rate of decline in BMD 
than those aged 45-49 years and 50-54 years at both the total hip and femoral neck. 
Thereafter, the rate of decline in BMD accelerated with advancing age. For example, the 
rate of decline in total hip BMD was -0.10±0.55 %/yr among men aged 55-59 years 
(P=0.009) and increased to -0.48±0.60 %/yr among men aged 70+ years (P<0.0001). 
Similar results were observed at the femoral neck.  
3.4.3 Age-adjusted correlates of the rate of change in BMD 
Table 2 shows the age-adjusted association of participant characteristics with the rate of 
decline in BMD at the total hip and femoral neck. Age was inversely and significantly 
correlated with the decline in BMD. For example, the rate of decline in total hip BMD 
increased by 0.084%/yr every 10 years.  
A 10 kg increase in body weight was associated with a slower rate of decline in 
total hip BMD. Body composition measures from DXA were significantly associated 
with the rate of decline in hip BMD. Whole body fat, lean mass and percent body fat 
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were all positively and significantly associated with the decline in hip BMD in age-
adjusted analysis. Initial BMD was not related to the subsequent rate of decline in BMD. 
  We also evaluated the relationship between annualized percent rate of decline in 
BMD and change in body weight and body composition over the follow-up period. Men 
gained an average of 0.2±6.2% body weight during follow-up (P=0.20). As expected, fat 
mass increased (P<.0001) whereas lean mass decreased non-significantly (P=0.25) during 
the follow-up period. In age-adjusted analysis, men who lost weight during follow-up had 
a significantly greater mean rate of decline in BMD. For example, every 6% decrease in 
body weight from baseline was associated with a 0.11%/yr decrease in total hip and a 
0.14%/yr decrease in femoral neck BMD. Similar associations were observed for the 
change in fat mass and lean mass.   
None of the lifestyle related characteristics examined were significantly 
associated with the annualized rate of decline in BMD including current and past 
smoking history, time spent watching television, and alcohol intake. Diabetes was present 
in about 11% of the cohort and was associated with a greater decline in total hip, but not 
femoral neck, BMD in age-adjusted analysis. Because there appeared to be a u-shaped 
relationship between age and the rate of decline in BMD, we also examined the correlates 
of bone loss in stratified analyses among men aged 40-54 and 55+ and found similar 
results as those in the total cohort (data not shown). 
We further evaluated the association of age, BMI, weight change and the 
interactions of these variables with the rate of decline in BMD in stratified analyses 
(Tables 3 and 4). At both the total hip and femoral neck, men who lost 5% or more of 
their baseline body weight had a significantly greater decline in BMD compared to men 
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who had remained weight stable or who gained 5% or more body weight.  There was also 
a significant loss of BMD among men who remained weight stable during follow-up.  
However, men who gained at least 5% body weight during follow-up did not experience 
a significant decline in hip BMD.  
We also found a significant interaction effect of age at study entry and weight 
change on the rate of decline in hip BMD (Table 3). The effect of weight loss on the 
decline in BMD was significantly greater (total hip, p=0.006; femoral neck, p=0.018) 
among older (age ≥ 55 yrs) than younger (age <55 yrs) men. Finally, we also observed a 
significant interaction effect of initial BMI and subsequent weight change on the rate of 
decline in total hip BMD (Table 4). Although weight gain was associated with an overall 
slower rate of decline in femoral neck BMD, this effect was not apparent among the 
leanest men. Men with a low initial BMI (BMI < 25.0 kg/m2) experienced a more 
pronounced rate of decline in BMD even if they had gained weight during follow-up. 
3.4.4 Multiple Linear Regression 
The results from multiple linear regression analyses of the independent correlates of the 
rate of decline in decline are shown in Table 5. Age(-), BMI(+), weight change(+), and 
grip strength(+) were significant correlates of the rate of decline in BMD in multiple 
regression analysis. Diabetes was no longer a statistically significant correlate of the rate 
of decline in total hip BMD in the multivariable model. Multivariate models only 
explained 5-6% of the variance in the rate of decline in BMD.   
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3.5 DISCUSSION 
Compared with women, much less is known about the magnitude and correlates of bone 
loss with aging in men, especially among non-white men. To our knowledge, only a 
single longitudinal study to date has evaluated age-related bone loss in men of African 
ancestry and that study only included 119 men aged 65 and older (14). Thus, one aim of 
the current study was to examine the pattern of BMD loss at the proximal femur over 4 
years in a large population sample of middle-aged and elderly men of African ancestry. A 
primary finding of our study is that BMD loss at the proximal femur is substantial and 
may begin early in life among men of African ancestry. This early decline in BMD may 
reflect, in part, an early loss of trabecular bone mass and a later loss of cortical bone mass 
from the proximal femur.  Indeed, others have recently observed a loss of trabecular 
BMD well before middle age among men (17,18).  However, the pattern of BMD loss 
with advancing age in our study appeared to be non-linear with a deceleration in the rate 
of loss between ages 40-54 and an acceleration in the rate of loss thereafter that continued 
unabated into the 7th decade of life.  A progressive acceleration of BMD loss with 
advancing age has also been observed among Caucasian men(3,13). Past epidemiologic 
studies of the decline in BMD have largely focused on Caucasian men aged ≥ 65 years 
and may have thus missed this early decline in hip BMD.     
In our study of Afro-Caribbean men aged 40-92 years, the overall unadjusted rate 
of decline in BMD at the femoral neck was -0.29±0.81 %/yr and was -0.47±0.89%/yr 
among men aged 65 years and older.  These rates of decline in BMD were surprisingly 
very similar to the rates of BMD decline reported in other longitudinal studies of 
Caucasian men(3-5,7,9). For example, in the Framingham Osteoporosis Study, the rate of 
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decline in femoral neck BMD was -0.38%/yr among 278 Caucasian American men aged 
67-90(4). In the Rotterdam Study, the rate of decline in femoral neck BMD was -0.4%/yr 
in 1856 Caucasian European men aged >55 yrs(3). In the Rancho Bernardo study, the rate 
of bone loss at the femoral neck was -0.34 %/yr in 500 Caucasian American men aged 
45-92 yrs(7). In the Network in Europe for Male Osteoporosis, the rate of decline in 
BMD at the femoral neck was -0.48%/yr among ~1300 Caucasian European men aged 
50-80 yrs(11). Finally, in the Baltimore Men’s Osteoporosis Study, the rate of decline in 
femoral neck BMD was -2.1%/yr in 349 Caucasian American and -1.1%/yr in 119 
African American men aged 60-74 yrs(14). The high rate of BMD loss in this study may 
reflect the use of different densitometers at the initial and follow-up exams. Comparisons 
across these studies are difficult to make and should be interpreted cautiously due to the 
differences in follow-up time, densitometers used, sample sizes, geographic areas, and 
age distributions of the populations studied. Nonetheless, the rate of decline in femoral 
neck BMD with aging in our cohort of Afro-Caribbean men is very consistent with the 
majority of these other studies of Caucasian men.  
To better understand the factors that might influence the rate of BMD loss with 
age in men of African ancestry, we characterized a number of anthropometric, lifestyle 
and medical variables and examined the relation of these variables to the rate of BMD 
loss at the proximal femur. In addition to advanced age, leanness at study entry and 
weight loss during follow-up were particularly important independent correlates of an 
increased rate of BMD loss with age. A positive association between body weight or BMI 
and BMD among middle-aged and elderly men has been well-documented in Caucasians 
and African Americans(19-24). Weight loss with aging is also a consistent predictor of 
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the rate of loss in BMD (4,6-8,25). In the present study, men who lost 5% of more of 
their baseline body weight had an accelerated rate of decline in BMD compared to men 
who remained weight stable or gained weight. The effect of weight loss on the age-
related decline in BMD was more profound among men aged 55 and older in our study. 
In the Framingham, Rancho Bernardo, Osteoporotic Fractures in Men (MrOS) and EPIC 
studies, Caucasian men who lost 5% or more of their baseline weight also had a 
significantly greater rate of BMD loss at the proximal femur than those who gained 5% 
or more of their baseline weight(4,6-8). The importance of weight loss as a risk factor for 
accelerated loss of BMD among middle-aged and elderly men may be explained by 
underlying illness that results in poor health and physical inactivity(8,25), to declines in 
muscle mass and strength, to decreased mechanical loading on weight-bearing skeletal 
sites (26,27), to a decrease in adipose tissue mass which is an important source of 
estrogens in men(28), or to a combination of these factors.   
Other frequently examined predictors of the age-related loss of BMD such as 
physical activity, smoking, calcium intake and medical conditions have yielded 
inconsistent results across studies(3,4,7,12). We also examined several of these variables 
that might affect the rate of decline in BMD with aging. Greater grip strength was 
associated with a slower loss of BMD, even after adjusting for age, body weight and 
weight change. The association with grip strength may be explained, in part, by increased 
physical activity and lean mass.  
We were unable to document an association between smoking and the rate of 
BMD loss in our study. Some(22,29-31), but not all(19,32,33), studies suggest that 
smokers have lower BMD than non-smokers in cross-sectional analyses. In Caucasian 
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men, smokers had a greater decline in hip BMD with age compared to non-
smokers(3,4,7,25). We were also unable to document an association between alcohol 
intake and the rate of decline in BMD. Moderate alcohol consumption has been 
associated with greater BMD in several(22,23,34), but not all(13,19), cross-sectional 
studies of middle-aged and elderly Caucasian men. Alcohol consumption was associated 
with a slower rate of age-related decline in BMD in some(7,35), but not all(4,25) 
longitudinal studies. The absence of a significant relationship with smoking and alcohol 
drinking in the current study may be due to a low prevalence of these behaviors.  
Two of the strongest contributors to the rate of decline in BMD in our 
study were advanced prostate cancer and ADT for prostate cancer. The association was 
independent of other covariates including body weight and weight change during follow-
up. Androgens increase bone formation and decrease bone resorption and ADT may 
disrupt this balance resulting in bone loss(36). ADT has been associated with a higher 
prevalence of osteoporosis among prostate cancer patients(37). Most of the longitudinal 
population-based studies in men did not examine the relationship between prostate cancer 
and changes in BMD with aging. Prostate cancer and its treatment might be particularly 
important risk factors for bone loss in men of African descent given its higher prevalence 
in men of African compared with Caucasian descent.
Our study has several limitations. The small proportion of older-aged men may 
have limited our ability to estimate the rate of bone loss in these men. Although walking 
is a common form of physical activity in this population, our questionnaire estimates of 
walking hours might not have been an accurate reflection of total physical activity levels.  
In addition, our DXA measures of areal BMD cannot provide insight on age-related loss 
  68
of trabecular and cortical bone mass or bone geometry. Three dimensional measures of 
trabecular and cortical volumetric BMD and bone structure would provide important 
insight on the aging skeleton in this population.  
In conclusion, although the prevalence of osteoporosis is higher among Caucasian 
than African ancestry men, men of African ancestry appear to experience a substantial 
loss of BMD with aging that may be comparable to the rate of loss in Caucasian men. 
Advancing age, lower body weight, increased weight loss, advanced prostate cancer and 
its treatment by androgen deprivation were identified as potential risk factors for 
accelerated loss of BMD in our study. However, these factors only explained 6% to 7% 
of the variation in the rate of decline in BMD with aging. These findings suggest that 
many other undetermined variables, including inherited factors, may contribute to age-
related loss of BMD in men of African ancestry. A more complete understanding of 
BMD changes with aging in men of African ancestry will require a broader examination 
of the potential determinants.  
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Table 3-1 Comparison of selected baseline characteristics among men who participated and did not 
participate in the follow-up exam 
 
 Participants 
(n=1748) 
Non-participants 
(n=904) 
P-value 
Age (yrs) 56.4±10.5 59.1±12.0 <.0001 
Height (cm) 174.8±6.6 174.6±6.7 .3810 
Weight (kg) 83.6±14.2 81.2±14.6 <.0001 
BMI (kg/m2) 27.3±4.1 26.5±4.2 <.0001 
Grip strength (kg) 43.0±9.8 40.6±11.1 <.0001 
Whole body fat (%) 20.1±5.8 19.9±6.2 .5877 
Total hip BMD (g/cm2)* 1.150±.147 1.123±.155 <.0001 
Femoral neck BMD (g/cm2)* 0.998±.147 0.961±.150 <.0001 
Worse health compared to 12 months ago (%) 12.1 18.0 <.0001 
Worse heath compared to men with the same age 
(%) 
2.5 5.5 .0001 
Ever Smoker (%) 38.2 48.8 <.0001 
Current smoker (%) 11.6 18.8 <.0001 
Drank alcohol > 4 times a week 16.2 18.8 .0975 
Fractured bone (%) 19.8 20.8 .5385 
Hypertension (%) 28.9 34.2 .0052 
Heart Disease (%) 3.4 5.9 .0026 
Diabetes (%) 11.2 14.8 .0084 
Arthritis (%)  11.7 15.5 .0064 
Prostate cancer (%) 13.8 14.2 .7633 
ADT treatment (%) 5.7 1.7 <.0001 
*Age-adjusted 
ADT, androgen deprivation treatment
  74
 
Age group
R
at
e 
of
 c
ha
ng
e 
in
 B
M
D
(%
/y
r)
-0.8
-0.6
-0.4
-0.2
0.0
0.2
Total Hip
Femoral Neck
 
 
Figure 3-1 Annualized rate of change in hip BMD by age group 
 
* Group-specific rate of change in BMD was not significantly different from zero. Rates of change in BMD 
were significantly different from zero for all other groups. P-values for overall association with age was 
<0.0001 for total hip and 0.0002 for femoral neck. Men with prostate cancer or who had undergone 
androgen deprivation therapy were excluded from the analysis. 
 
    40-44       45-49       50-54      55-59       60-64       65-69      70-74         75+
    n=237      n=298      n=283     n=191      n=186      n=122       n=78        n=63
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Table 3-2 Correlates of the rate of change in hip BMD* 
Variables (baseline) 
Mean ± SD 
or 
prevalence 
(%) 
Unit 
Age-adjusted rate of change in BMD (95%CI) 
Total Hip Femoral Neck 
Demographic characteristics 
 Age (years) 54.8±10.0 10 -0.084 (-0.112, -0.055) -0.053 (-0.095, -0.011) 
 Mixed African ancestry 11.2% Yes 0.037 (-0.052, 0.126) 0.105 (-0.028, 0.238) 
Occupational history     
 Ever work on farm 51.1% Yes -0.009 (-0.065, 0.048) -0.023 (-0.107, 0.061) 
 Ever work on fishing boat 17.0% Yes -0.012 (-0.087, 0.062) -0.061 (-0.172, 0.051) 
Anthropometric & DXA measures 
 Body weight (kg) 84.0±14.2 10 0.040 (0.020, 0.059) 0.065 (0.035, 0.094) 
 BMI 27.3±4.1 4.1 0.057 (0.029, 0.085) 0.094 (0.052, 0.137) 
 Height 175.1±6.5 6.5 0.029 (0.000, 0.058) 0.032 (-0.011, 0.075) 
 Grip strength 44.0±9.6 9.6 0.030 (-0.003, 0.063) 0.074 (0.025, 0.124) 
 Total hip BMD (g/cm2) 1.16±0.14 0.14 0.004 (-0.024, 0.032) - 
 Femoral neck BMD (g/cm2) 1.00±0.15 0.15 - 0.008 (-0.037, 0.052) 
 Fat mass (kg) 16.3±6.5 6.5 0.069 (0.041, 0.097) 0.101 (0.059, 0.143) 
 Lean mass (kg) 64.9±8.5 8.5 0.034 (0.005, 0.064) 0.064 (0.021, 0.108) 
 Body fat (%) 19.7±5.7 5.7 0.079 (0.051, 0.108) 0.104 (0.061, 0.146) 
 Weight change (%) 0.2±6.2 6.2 0.108 (0.078, 0.137) 0.158 (0.114, 0.201) 
 Fat mass change (%) 6.4±18.1 18.1 0.062 (0.033, 0.091) 0.101 (0.059, 0.143) 
 Lean mass change (%) -0.1±3.6 3.6 0.132 (0.103, 0.161) 0.136 (0.092, 0.180) 
Lifestyle characteristics 
 Ever smoker 38.5% Yes 0.009 (-0.049, 0.066) 0.029 (-0.057, 0.115) 
 Current smoker 12.0% Yes -0.064 (-0.150, 0.023) -0.091 (-0.220, 0.038) 
 TV watching ≥21 hrs per week 31.1% Yes 0.036 (-0.025, 0.097) 0.027 (-0.063, 0.118) 
 Drink alcohol ≥4 times per week 15.9% Yes 0.001 (-0.078, 0.080) 0.026 (-0.093, 0.144) 
Medical History 
 Ever fractured bone 20.2% Yes -0.015 (-0.085, 0.055) -0.007 (-0.111, 0.098) 
 Hypertension 27.6% Yes 0.037 (-0.027, 0.102) 0.065 (-0.031, 0.161) 
 Diabetes 10.7% Yes -0.102 (-0.195, -0.008) -0.028 (-0.167, 0.111) 
 Arthritis 10.6% Yes 0.015 (-0.080, 0.111) 0.053 (-0.089, 0.195) 
*Expressed as absolute difference in annualized rate of change in BMD change per unit of the predictor 
variable. Men with prostate cancer or who had undergone androgen deprivation therapy were excluded 
from the analysis 
Bold: p-value<0.05 
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Table 3-3 Mean annualized rate of change in hip BMD by category of percent weight change and Age 
Category of  
weight change 
Mean annualized % change in hip BMD(95%CI)* 
Overall cohort Age Age 40-54 Age 55+ 
Total hip  n=768 n=590 
  Weight loss(n=216) -0.340(-0.413, -0.267) -0.204(-0.325, -0.085) -0.418(-0.509, -0.326) 
  Stable weight(n=878) -0.062(-0.097, -0.026) -0.030(-0.077, 0.016) -0.106(-0.162, -0.051) 
  Weight gain(n=274) 0.003(-0.031, 0.067) 0.070(-0.009, 0.149) -0.122(-0.230, -0.015) 
Femoral neck**  n=765 n=596 
  Weight loss(n=220) -0.609(-0.716, -0.502) -0.437(-0.615, -0.259) -0.705(-0.839, -0.572) 
  Stable weight(n=874) -0.252(-0.305, -0.199) -0.273(-0.342, -0.204) -0.222(-0.304, -0.141) 
  Weight gain(n=273) -0.088(-0.182, 0.007) -0.048(-0.165, 0.069) -0.161(-0.321, -0.002) 
Weight loss was defined as a loss of 5% or more of body weight from the baseline exam. 
Weight gain was defined as a gain of 5% or more of body weight from the baseline exam. 
* Adjusted for BMI 
**The interaction term between weight change and age categories was significant for femoral neck only 
(p=0.03). Men with prostate cancer or who had undergone androgen deprivation therapy were excluded 
from the analysis. 
 
 
Table 3-4 Mean annualized rate of change in hip BMD by category of percent weight change and 
BMI 
 
Category of  
weight change 
Mean annualized % change in hip BMD(95%CI)* 
Overall cohort BMI BMI<25kg/m2 BMI 25.0-29.9 kg/m2 BMI≥30kg/m2 
Total hip**  n=385 n=655 n=318 
  Weight loss(n=210) -0.308(-0.381, -0.235) -0.279(-0.447, -0.112) -0.289(-0.393, -0.186) -0.327(-0.458, -0.196) 
  Stable weight(n=874) -0.066(-0.102, -0.030) -0.186(-0.253, -0.118) -0.043(-0.093, 0.007) 0.037(-0.039, 0.113) 
  Weight gain(n=274) -0.014(-0.078, 0.051) -0.027(-0.132, 0.078) -0.091(-0.190, 0.008) 0.140(0.004, 0.276) 
Femoral neck  n=390 n=657 n=314 
  Weight loss(n=214) -0.585(-0.692, -0.478) -0.598(-0.841, -0.355) -0.663(-0.816, -0.510) -0.436(-0.630, -0.242) 
  Stable weight(n=874) -0.252(-0.305, -0.199) -0.381(-0.481, -0.282) -0.228(-0.303, -0.154) -0.146(-0.260, -0.032) 
  Weight gain(n=273) -0.106(-0.201, -0.011) -0.271(-0.427, -0.113) -0.049(-0.196, 0.099) 0.079(-0.125, 0.283) 
Weight loss was defined as a loss of 5% or more of body weight from the baseline exam. 
Weight gain was defined as a gain of 5% or more of body weight from the baseline exam. 
* Adjusted for age 
**The interaction term between weight change and BMI categories was significant for total hip only 
(p=0.02). Men with prostate cancer or who had undergone androgen deprivation therapy were excluded 
from the analysis. 
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Table 3-5 Multivariable correlates of the annualized rate of change in BMD in older Afro-Caribbean 
men 
 
Variable Unit 
Rate of change in BMD (95%CI) per unit 
Total Hip1 Femoral Neck2 
   (n=1358)  (n=1370) 
Age (years)3 10 -0.056 (-0.0856, -0.027) 0.026 (-0.025, 0.078) 
BMI (kg/cm2) 4.1 0.073 (0.043, 0.102) 0.101 (0.057, 0.146) 
Weight change (%) 6.2 0.112 (0.082, 0.142) 0.167 (0.123, 0.211) 
Grip strength (kg) 9.6 - 0.055 (0.004, 0.106) 
Model R2  0.07 0.06 
1Age, BMI, weight change, grip strength, and diabetes were entered into the model 
2Age, BMI, weight change and grip strength were entered into the model  
3Age was forced into the model 
Bold: p-value less than 0.05 
Men with prostate cancer or who had undergone androgen deprivation therapy were 
excluded from the analysis. 
- : variable was entered into the model but not a significant in the final model  
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4.1 ABSTRACT 
Quantitative computed tompgraphy (QCT) is a 3-dimensional imaging technique that is 
able to distinguish trabecular and cortical bone and provide a measure of volumetric bone 
mineral density (vBMD). Very few studies have examined the factors related to vBMD in 
men, especially men of African heritage. The present study evaluated comprehensively 
the relationship of vBMD with demographic, anthropometric, medical and behavioral 
factors in a large cohort of men of African heritage (n=1,901) aged 40 years and older. 
Trabecular and cortical vBMD were measured by peripheral QCT (pQCT) at the radius 
and tibia. Trabecular vBMD decreased dramatically before age of 50 and then remained 
similar or decreased slightly thereafter. In contrast, cortical vBMD decreased steadily 
with advancing age.  Step-wise multiple linear regression analysis identified, age, body 
weight, cigarette smoking, and a history of type II diabetes and prostate cancer as the 
major correlates of vBMD. However, different relationships between cortical and 
trabecular vBMD and skeletal site were observed for several variables. Our findings 
suggest that there are different age patterns and correlates for trabecular and cortical 
vBMD in men of African ancestry.  A better understanding of the mechanisms underlying 
these differential associations may reveal new insight into the etiology of age-related 
bone loss and osteoporosis. 
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4.2 INTRODUCTION 
 
Bone mineral density (BMD) measured by dual-energy x-ray absorptiometry (DXA) has 
been widely used to diagnose osteoporosis and to identify subjects at risk for fracture and 
factors for osteoporosis. However, DXA is a two-dimensional imaging technique that 
measures areal BMD (aBMD), cannot distinguish between trabecular and cortical bone, 
and is confounded by differences in bone size. Unlike DXA, quantitative computed 
tomography (QCT) measures volumetric BMD (vBMD), provides a separate measure of 
trabecular and cortical BMD, and is not confounded by bone size differences between 
individuals. 
Factors related to DXA-measured aBMD have been well-established. In contrast, 
few studies have comprehensively characterized the anthropometric, medical and 
behavioral factors related to trabecular and cortical vBMD. Moreover, there is limited 
information available on the correlates of vBMD in populations of African descent (1-3). 
In the present study, we examined the factors related to trabecular and cortical vBMD in 
a large population-based study of men of African ancestry. The aim of our study was to 
identify the correlates of vBMD and to compare the factors associated with cortical and 
trabecular vBMD.  
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4.3 METHODS 
4.3.1 Study subjects 
Between 1997 and 2003, 3,170 men were recruited for a population-based prostate cancer 
screening study on the Island of Tobago, Trinidad & Tobago (4). Briefly, the Tobago 
Prostate Cancer Survey is an observational cohort study of prostate cancer prevalence and 
incidence in otherwise healthy men aged 40 years and older.  To be eligible, men had to 
be ambulatory, non-institutionalized and not terminally ill. Recruitment for the survey 
was accomplished by flyers, public service announcements, posters, informing health 
care workers at local hospital and health centers, and word of mouth. Approximately 60% 
of all age-eligible men on the island participated and participation was representative of 
the island Parishes. The cohort is 97% African, 2% East Indian, <1% white, and <1% 
"other" as defined by paternal and maternal grandparent's ethnicity.  
Between 2004 and 2007, men were invited back for a follow-up examination and 
to complete a peripheral QCT (pQCT) scan. A total of 2031 men in the prostate cohort 
(70% of survivors) returned for the visit. At the follow-up visit, we also recruited 451 
new participants. Of them, 2153 underwent pQCT scan at the radius and tibia. We also 
excluded men with incomplete data or of non Afro-Caribbean origin. The current analysis 
is limited to the 1,901 men of African descent with complete pQCT scans and available 
information from questionnaire interview by the time the analysis was complete.    
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4.3.2 Anthropometric and body composition measurements 
Body weight (in kilograms) was measured with light clothing and without shoes using a 
calibrated balance beam scale. Height (in centimeters) was measured without shoes using 
a wall-mounted height board. Two height measurements were made and the average used 
in analysis. Waist circumference was measured at the umbilicus with an inelastic tape 
measure. Body mass index (BMI) was calculated as weight in kilograms divided by 
height in meters squared. Handgrip strength was measured in kilograms for both the left 
and right hands as a surrogate for upper body and overall strength using a dynamometer 
(Preston Grip Dynamometer, JA Preston 136 Crop.). Body composition (bone mineral-
free lean mass and fat mass) was measured using a Hologic QDR-4500W DXA scanner 
(Hologic Inc., Bedford, MA). For all participants, the same scanner was used and DXA 
scans were completed using the array beam mode.  Standardized positioning and 
utilization of QDR software was based on the manufacturer’s recommended protocol.  
Scans were analyzed with QDR software version 8.26a.  To ensure consistency, the DXA 
technician scanned a spine phantom daily and completed a weekly quality control whole 
body air scan, prior to completing any participant scans. 
4.3.3 Other measurements 
Trained interviewers and nurses administered questionnaires to participants. 
Questionnaires gathered information pertaining to demographic characteristics, medical 
history, fracture history, physical activity, and lifestyle variables.  We focused on 
potential correlates of vBMD based on the body of literature for men and women.  
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Ethnicity was self-reported and participants provided detailed information on the ethnic 
origin of their parents and grandparents. Respondents were assigned to an ethnic group if 
they reported that all four grandparents as belonging to that group.  Afro-Caribbean men 
who reported having less than 4 African grandparents were categorized as mixed African 
ethnicity.  Occupational history was measured as a dichotomous variable and included 
several common occupations.   
Participants were asked whether they had been diagnosed by a health care 
provider with selected conditions including cardiovascular disease, diabetes, hypertension 
and prostate cancer. We also obtained information on personal and parental fracture 
history. Disability was assessed with questions about the degree of difficulty (no 
difficulty; some difficulty; much difficulty; or unable to perform activity) in six activities 
of daily living that involved the back (bending down to pick up light-weight objects, 
lifting a 10-pound object from the floor, reaching for objects just above the head, putting 
on socks or stockings, getting in and out of an automobile, and standing for 2 hours). 
Subjects answered any difficulty or unable to perform any of the six activities due to back 
pain were considered with “difficulty performing daily activity due to back pain”.   
Smoking status was categorized as never, past and current by asking men whether 
they had smoked at least 100 cigarettes in their lifetime. Men who smoked fewer than 
100 cigarettes were considered to have never smoked. Weekly alcohol drinking in the 
past 12 months was categorized as none, occasional drinking, and 1-3, 4-7, 8-14, 15-21, 
22-27 and more than 28 drinks per week. Physical activity was assessed by the frequency 
and duration of walking in the past 7days for exercise, to work, the store or church. We 
also used hours of television watching per week as a surrogate of physical inactivity. 
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Men also reported their daily consumption of coffee, tea and soda (not 
decaffeinated). We assumed that one cup of coffee, tea and soda contained 95, 55 and 
45mg of caffeine, respectively. Dietary calcium intake was assessed by frequency of 
selected food items including fish, bone chewing, green leafy vegetables, beans, milk, 
cheese, and cheese dishes that contain high dietary calcium and are frequently consumed 
in the local cuisine. Supplemental intake of calcium and vitamin D was also assessed.  
4.3.4 Peripheral QCT 
Peripheral QCT was performed at the non-dominant forearm and left tibia (4% and 33% 
of the total length of forearm and tibia), two skeletal sites that are subjected to different 
weight bearing, using the Stratec XCT-2000 scanner (Stratec Medizintechnik, Pforzheim, 
Germany). Technicians followed a stringent protocol for patient positioning and 
scanning. A scout view was obtained prior to the pQCT scan to define an anatomic 
reference line for the relative location of the subsequent scans at the radius and tibia. 
Tibia length was measured from the medial malleolus to the medial condyle of the tibia, 
and forearm length was measured from the olecranon to the ulna styloid process. The 
scans at the 4% radius and tibia sites represent predominantly trabecular bone, whereas 
the scans at the 33% sites represent predominantly cortical bone. A single axial slice of 
2.5mm thickness with a voxel size of 0.5mm and a speed of 20 mm/s is taken at all 
locations. Image processing was performed using the Stratec software package (Version 
5.5E). To determine the total and trabecular vBMD (mg/cm3) at the 4% site of the radius 
and tibia, identical parameters for contour finding and separation of tabecular and cortical 
bone are: contour mode 2, Threshold=169 mg/cm3; peel mode 1, area=45%. To 
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determine the total and cortical vBMD (mg/cm3) at the 33% site of the radius and tibia, 
identical parameters are: mode 2, Threshold=169 mg/cm3;cortmode 1, Threshold=710 
mg/cm3. pQCT scans were stable throughout the study. The short-tern in vivo precision 
of pQCT measurements was evaluated in 30 subjects. All CVs for measures of pQCT 
BMD were 2.1%. 
4.3.5 Statistical Analysis   
Analysis of variance (ANOVA) was used to compare the unadjusted skeletal site-specific 
vBMD across 5-year age groups. We also evaluated the age-adjusted, and age and 
weight- adjusted (data not shown) association of each predictor with cortical and 
trabecular vBMD at the radius and tibia using linear regression analysis. The 
relationships between potential correlates and vBMD were expressed as a one unit 
increase for categorical variables or approximately a one standard deviation (SD) 
increase for continuous variables, along with 95% confidence intervals. The formula used 
to calculate the percent difference in vBMD per unit change of independent variable was: 
((β coefficient *unit)/ mean vBMD)*100. The corresponding confidence intervals were 
calculated as: (((β coefficient ± 1.96*standard error)*unit)/mean vBMD)*100. In order to 
identify the independent correlates, multiple linear regression analysis was performed 
separately using a stepwise procedure for trabecular and cortical vBMD at the radius and 
tibia. Age was forced into each multiple linear regression model. Variables with a p-value 
less than 0.10 from the age-adjusted univariate linear regression model were entered into 
the multiple variable model. We also assessed the multi-collinearity of predictor variables 
using the variance inflation factor (VIF). If there was evidence of collinearity, the model 
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was re-evaluated. If variables were from the same domain (e.g., “ever smoked” and 
“currently smoke”), we selected the variable with a stronger association with vBMD. In 
addition, multiple linear regression analyses of vBMD at each skeletal site were 
performed for three separate models that included anthropometric or body composition 
variables: 1) using BMI; 2) using body weight and height modeled separately; and 3) 
using total body fat and lean mass. Results were similar and thus only the results for BMI 
are shown. All statistical analyses were performed using the Statistical Analysis System 
(SAS, version 9.1; SAS Institute, Cary, NC). 
4.4 RESULTS 
The mean age of the population was 59.1±10.4 years old (range 40-92 years old). 
Approximately 9% of the men reported having at least one non-African grandparent. The 
mean values and standard deviation (SD) of trabecular and cortical vBMD were 206±49 
and 1213±23 mg/cm3 at the radius, and 228±41 and 1177±24 mg/cm3 at the tibia. Figure 
4-1 and 4-2 shows the unadjusted age-related patterns for trabecular and cortical vBMD 
at each skeletal site. The pair-wise t-test showed that the oldest age group (75+) had a 
17% and 5% lower trabecular vBMD than the youngest age group (40-44) at the radius 
(p<0.0001) and tibia (p=0.10), respectively. Men aged 45-49 had a 9% (p=0.01) and 4% 
lower (p=0.01) trabecular vBMD than those aged 40-44 at the radius and tibia, 
respectively, but trabecular vBMD did not differ substantially between the older age 
groups. Cortical vBMD was 2% (p<0.0001) and 1% (p=0.0003) lower for the oldest age 
group at the radius and tibia, respectively, compared to the youngest age group.  
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4.4.1 Age-adjusted regression results 
Each SD (4.3 kg/m2) increase in BMI was associated with a 3.0% and 4.6% higher 
trabecular vBMD and 0.37% and 0.36% lower cortical vBMD at the radius and tibia, 
respectively (Table 4-1). In general, the body weight and body composition related 
variables were positively correlated with trabecular vBMD, whereas these variables were 
negatively associated with cortical vBMD. In addition, every 6.7cm increase in height 
was associated with a 4% lower trabecular vBMD at both the tibia and radius, but a 0.1% 
higher cortical vBMD at the radius.  
The prevalence of self-reported diabetes was 16.4% and was positively associated 
with vBMD at all 4 skeletal sites with an approximately 4% and 5% higher trabecular 
vBMD but only 0.4% higher cortical vBMD than men without diabetes. Mixed African 
ancestry, prostate cancer history and androgen deprivation therapy (orchiectomy or 
currently taking Leuprorelin) was associated with a 0.3% to 0.9% lower cortical vBMD 
but these variables were not associated with trabecular vBMD. Men who had experienced 
a previous fracture had lower trabecular and cortical vBMD, but the association was only 
significant for trabecular vBMD at the radius and cortical vBMD at the tibia. Use of 
thiazide or non-thiazide diuretics was not associated with trabecular or cortical vBMD. 
Glucocorticoids use was low in this population and was not significantly associated with 
vBMD at either skeletal site.  
Men who smoked more than 100 cigarettes in their lifetime had a 4-5% lower 
trabucular vBMD and approximately 0.2% lower cortical vBMD than nonsmokers. 
Moreover, the effect of smoking on vBMD was greater for current smokers than past 
smokers, compared with nonsmokers. Alcohol drinking and physical activity were not 
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correlated with vBMD. Fifteen percent of the men chewed animal or fish bones at least 5 
days a week. Bone chewing was associated with a 2-3% higher trabecular vBMD at both 
skeletal sites but was not associated with cortical vBMD. 
4.4.2 Results from the multiple linear regression model 
Age(-), body weight(+), height(-), diabetes(+), personal fracture history(-), cigarette 
smoking (-), and bone chewing(+) explained 6% of the variation in trabecular vBMD at 
the radius (Table 4-2). These variables, except fracture history, explained 10% of the 
variation in trabecular vBMD at the tibia. Multiple linear regression models explained 16 
and 13% of the variation in cortical vBMD at the radius and tibia, respectively. At the 
radius, age(-), body weight(-), height(+), grip strength(-), mixed African ethnicity(-), 
diabetes(+), prostate cancer(-), androgen deprivation therapy(-), and smoking(-) were 
significant correlates of cortical vBMD. However, for cortical vBMD at the tibia, only 
age(-), weight(-), diabetes(+) and androgen deprivation therapy(-) remained in the final 
model.   
Multiple linear regression models substituting BMI or body fat and lean mass for 
body weight yield similar results (data not shown). BMI was positively associated with 
trabecular vBMD, but negatively associated with cortical vBMD. In the models that 
included body fat and lean mass, lean mass was a significant positive correlate of 
trabecular vBMD but negative correlate of cortical vBMD. Fat mass and vBMD were 
only significantly correlated at the tibia. Fat mass was positively associated with 
trabecular vBMD but was negatively associated with cortical vBMD at the tibia. 
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4.5 DISCUSSION 
To better understand the factors that influence bone mass in men of African heritage, we 
characterized a number of anthropometric, lifestyle and medical variables and examined 
the relation of these variables to BMD at the radius and tibia in a large population sample 
of middle-aged and elderly men. Several features of our study were unique, including the 
large sample size of Afro-Caribbean men, careful measurement of variables, focus on 
both cortical and trabecular volumetric BMD, and the wealth of information available 
about the study cohort. The results validate associations described previously among 
Caucasian men, such as the major importance of body weight, but also illuminate 
previously unrecognized relationships. 
Bone mineral density decreases with advancing age in men of all race and ethnic 
background, and this trend most likely contributes to the increase in fracture rates with 
aging.  In the current study, we observed different age-related patterns for cortical and 
trabecular vBMD.  Similar results have been observed in other recent studies, but these 
reports have included only Caucasian men. We found that cortical vBMD appeared to 
decrease more slowly with advancing age than trabecular vBMD and the age pattern 
appeared to be more linear for cortical vBMD.  Cross-sectionally, the largest decline in 
trabecular vBMD occurred among men aged 40-44 and 45-49 years and then trabecular 
vBMD appeared to decline more slowly at the radius or remained stable at the tibia. 
Although our study did not include men aged 40 and below, our results among men of 
African ancestry appear to be consistent with the recent observations of an early 
reduction of trabecular vBMD with aging in men (5,6).  
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DXA measures of areal BMD are one of the most important predictors of 
osteoporotic fracture risk. Fewer studies have examined pQCT or QCT measures of 
vBMD and fracture in men, particularly among men of African ancestry. Among men 
and women, those with vertebral fracture have lower cortical and trabecular vBMD 
compared to controls (7). Each SD decrease in cortical, but not trabecular, vBMD at the 
radius was associated with a 16-fold risk of fracture among 52 hemodialysis patients (8). 
In our study, men who had experienced a previous fracture had significantly lower 
trabecular vBMD at the radius independent of other variables. 
Previous studies using ancestry informative molecular markers in this Afro-
Caribbean population have indicated that the ancestral proportions are 94.0% African, 
4% European and 1% Native American. Despite the low level of admixture in this 
population, we found that mixed African ancestry was associated with lower cortical 
vBMD at the radius. These results are consistent with previous studies which have 
observed lower aBMD among African Americans who have greater European ancestry 
(9). The high proportion of African ancestry and negative impact of admixture on vBMD 
implies that the Tobago population may benefit from a greater prevalence of protective 
alleles of African origin.  
Previous studies have found that greater body weight is associated with higher 
areal BMD in Caucasians and African Americans (10-12). In the present study, greater 
body weight, fat mass and lean mass were all associated with higher trabecular vBMD.  
In contrast, these variables were associated with lower cortical vBMD. Our results are 
consistent with the recent findings of Lorentzon et al. who showed that greater fat mass is 
associated with lower cortical vBMD at the tibia (13). Increased adipocytes in the bone 
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marrow cavity among heavier subjects may suppress osteoblastogenesis and contribute to 
decreased cortical vBMD by producing adipokines in the local bone micro-environment 
(14). 
In our study, diabetes was associated with greater cortical and trabecular vBMD 
and remained a significant correlate after adjusting for age, body weight and other 
covariates. A higher trabecular vBMD was observed in diabetic than non-diabetic black 
women and white men in the Health, Aging, and Body Composition Study (15). A 
similar association was not observed among white women or black men in the same 
study. In the Diabetes Heart Study, trabecular vBMD was not associated with diabetes 
independently from BMI (16).  
Androgens are a strong positive regulator of bone mass in men.  Several studies 
have revealed that androgen deprivation for treatment of prostate cancer is associated 
with a marked loss of bone mass (17-19). However, studies evaluating the effect of 
androgen deprivation on bone mass in men of African descent are limited.  Agarwal et al. 
reported a significant loss of trabecular vBMD at the lumbar spine after orchiectomy in 
Indian patients (20). We found significantly lower cortical, but not trabecular, vBMD 
among men who had a history of androgen deprivation therapy in the current study.  
Cigarette smoking was associated with lower trabecular but not cortical vBMD in 
our study. The GOOD study also did not observe a difference in cortical vBMD between 
Caucasian European men who did and did not smoke (21). The effect of smoking on 
trabecular vBMD in the current study was greater for current smokers, but was also 
evident among past smokers. This suggests that smoking may have a long-lasting effect 
on vBMD. The association with vBMD was also observed in the multivariable model, 
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indicating that the association was independent of other intervening variables such as 
body weight, alcohol intake and physical activity.   Nicotine may directly affect bone 
metabolism and bone mass by inhibiting the proliferation of osteoprogenitor cells in a 
concentration-dependent manner (22,23).  
Our multivariate models explained up to 16% of the variance in cortical vBMD.  
Only 10% of the variance in trabecular vBMD could be explained by the variables 
studied. These estimates compare well with other reports of DXA measures of areal 
BMD in men and women (24-28) and trabecular vBMD in men (3). However, these 
findings raise the possibility that many other undetermined variables, including inherited 
factors, contribute to cortical and trabecular vBMD in men of African heritage. 
In multivariate analyses, we found no association of vBMD with several lifestyle 
and behavioral variables including physical activity and intake of alcohol, caffeine and 
dietary calcium.  Use of diuretics was also not associated with vBMD in the current 
study.   Although dietary calcium intake was not associated with vBMD, we did observe 
an association between chewing bones and increased trabecular vBMD in multi-variate 
models. The absence of an association with some variables could reflect low statistical 
power to detect an association or the inherent difficulty in quantifying some variables 
with questionnaires. 
This study has several potential limitations. First, the cross-sectional design limits 
our ability to establish temporal relationships with trabecular and cortical vBMD. 
Confirmation of our results with longitudinal evaluations would be useful, particularly for 
establishing the tempo and natural history of trabecular and cortical bone loss in this 
population.  We also examined Afro-Caribbean men who were volunteers and their 
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characteristics may differ from those of other groups. Information collected by 
questionnaires depended on participants’ recall and this may have limited our ability to 
detect relationships.  On the other hand, our study has several unique features including 
its large size, focus on individuals of African heritage, careful delineation of trabecular 
and cortical BMD with QCT, and the wealth of information available on the study cohort. 
In summary, our study of a large group of older men of African ancestry supports 
the importance of several factors associated with volumetric BMD.  From a clinical 
perspective, these findings reinforce the need to avoid excessive thinness and cigarette 
smoking, a negative impact of androgen deprivation for prostate cancer, and the 
importance of calcium for preserving vBMD.  Our study also revealed a potentially 
negative impact of increased body weight and fat mass on cortical vBMD.          
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Figure 4-1 Trabecular vBMD by age group (unadjusted) 
Figure 4-2 Cortical vBMD by age group (unadjusted) 
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Table 4-1 Correlates of trabecular and cortical vBMD 
 
 
Variable 
Mean (±SD) 
or frequency 
(prevalence) 
Unit Age- and weight- adjusted percent difference change in vBMD per unit change 
(95%CI) 
Radius Tibia 
Trabecular vBMD Cortical vBMD Trabecular 
vBMD 
Cortical vBMD 
Age(yrs)§ 59.1±10.4 10 -2.62(-3.65, -1.58) -0.62(-0.70, -0.54) -0.09(-0.88, 0.69) -0.52(-0.61, -0.43) 
Body weight (kg)* 83.9±14.5 10 1.11(0.35, 1.87) -0.26(-0.31, -0.20) 2.36(1.79, 2.94) -0.32(-0.37, -0.25) 
Standing height (cm) 175.0±6.7 6.7 -4.07(-5.25, -2.89) 0.11(0.02, 0.20) -4.18(-5.05, -3.30) -0.08(-0.17, 0.02) 
BMI(kg/m2)* 27.4±4.3 4.3 3.00(1.93, 4.07) -0.37(-0.45, -0.28) 4.63(3.83, 5.42) -0.36(-0.45, -0.27) 
Waist circumference (cm) 93.1±10.7 10.7 0.76(-1.46, 2.97) 0.03(-0.13, 0.20) 2.70(1.06, 4.35) 0.15(-0.03, 0.33)¶ 
Grip strength (kg) 42.7±10.1 10.1 0.21(-1.19, 1.60) -0.09(-0.19, 0.01)¶ -1.24(-2.29, -0.20) -0.12(-0.23, -0.00) 
Daily dietary calcium intake (kg) 465.4±219.3  0.60(-0.48, 1.68) 0.02(-0.07, 0.10) 0.67(-0.13, 1.48)¶ -0.00(-0.09, 0.08) 
Daily caffeine intake in top quartile 364(20.0)  0.47(-2.29, 3.23) -0.20(-0.41, 0.00)¶ 0.99(-1.07, 3.05) -0.10(-0.32, 0.12) 
Total body fat mass (kg)* 17.6±6.9 6.9 1.53(0.45, 2.62) -0.30(-0.38, -0.22) 3.29(2.48, 4.11) -0.33(-0.42, -0.24) 
Total body lean mass (kg)* 64.2±8.7 8.7 1.50(0.33, 2.67) -0.88(-1.09, -0.67) 6.88(4.75, 9.01) -1.16(-1.39, -0.93) 
Percent fat mass (%)* 21.0±5.9 5.9 5.15(1.24, 9.06) -0.36(-0.49, -0.24) 4.69(2.48, 5.90) -0.36(-0.50, -0.23) 
Mixed African ancestry 170(8.9)  -1.20(-4.95, 2.55)  -0.37(-0.65, -0.08)  2.09(-0.70, 4.89) -0.31(-0.61, -0.01) 
Diabetes 311(16.4)  3.45(0.48, 6.42) 0.40(0.18, 0.62) 5.22(3.01, 7.43) 0.37(0.13, 0.62) 
Hypertension 620(32.8)  0.31(-2.09, 2.71) 0.04(-0.14, 0.22) 1.17(-0.63, 2.96) 0.10(-0.09, 0.29) 
CVD 67(3.5)  2.08(-3.74, 7.9) 0.20(-0.24, 0.64) 3.17(-1.30, 7.63) 0.07(-0.42, 0.55) 
Prostate cancer 291(15.3)  -0.25(-3.43, 2.92) -0.39(-0.63, -0.15) 0.03(-2.36, 2.43)  -0.33(-0.59, -0.07) 
Androgen deprivation therapy 61(3.3)  2.18(-4.05, 8.41) -0.84(-1.33, -0.35) 0.64(-4.04, 5.32) -0.88(-1.42, -0.35) 
Good overall health status  1718(91.3)  1.74(-2.14, 5.62) -0.04(-0.33, 0.25) 0.27(-2.65, 3.20) -0.29(-0.61, 0.02)¶ 
Ever fracture 367(19.3)  -3.24(-5.97, -0.51) -0.18(-0.39, 0.02)¶ -1.52(-3.55, 0.51) -0.26(-0.48, -0.04)  
Mother had fracture 80(4.9)  -4.64(-9.98, 0.69)¶ 0.03(-0.37, 0.43) -1.50(-5.45, 2.46) -0.04(-0.47, 0.38) 
Father had fracture  68(4.3)  -0.80(-6.62, 5.02) -0.34(-0.78, 0.10) 0.50(-3.77, 4.78) -0.38(-0.84, 0.09) 
Paternal or maternal fracture history 141(9.3)  -2.84(-6.98, 1.30) -0.16(-0.47, 0.15) -0.54(-3.59, 2.51) -0.26(-0.59, 0.08) 
Difficulty perform daily activity due to 
back pain 176(9.8)  -2.89(-6.77, 0.98) -0.20(-0.49, 0.10) -1.20(-4.17, 1.76) -0.11(-0.43, 0.22) 
Ever smoked 619(32.7)  -5.16(-7.44, -2.88) -0.19(-0.36, -0.02) -3.89(-5.59, -2.19) -0.18(-0.36, 0.01)¶ 
Smoking status       
    Past smoker vs. non smoker 420(22.2)  -3.74(-6.36, -1.12) -0.16(-0.35, 0.04) -3.06(-5.02, -1.09) -0.12(-0.36, 0.06) 
    Current smoker vs. non smoker 199 (10.5)  -8.17(-11.77, -4.58) -0.27(-0.54, -0.00) -5.61(-8.26, -2.96) -0.23(-0.52, 0.06) 
Alcohol intake≥1 drink/wk 358(18.9)  -1.96(-4.71, 0.79) 0.13(-0.08, 0.33) -1.47(-3.51, 0.57) 0.12(-0.10, 0.34) 
TV watching ≥ 14 hours/wk 722(38.2)  0.01(-2.21, 2.22) 0.12(-0.04, 0.29) -0.58(-2.24, 1.07) 0.19(0.01, 0.37) 
Walk ≥ 3.5 hours/wk 545(29.1)  -0.72(-3.11, 1.68) 0.06(-0.12, 0.24) 0.29(-1.49, 2.08) -0.00(-0.20, 0.19) 
Walk ≥ 5-7days/wk 1192(63.1)  0.18(-2.06, 2.42) -0.11(-0.28, 0.06) 1.13(-0.55, 2.79) -0.03(-0.21, 0.15) 
Bone chewing > 5 days/wk 278(14.8)  3.32(0.27, 6.37) 0.01(-0.22, 0.23) 2.38(0.10, 4.65) 0.01(-0.24, 0.25) 
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Table 4-1 (continued) Correlates of trabecular and cortical vBMD 
≥1 glass/d milk during teens 1588(84.2)  0.57(-2.38, 3.52) -0.02(-0.24, 0.20) 0.73(-1.48, 2.94) 0.07(-0.17, 0.31) 
≥1 glass/d milk at age 18-50 y 1260(67.0)  1.28(-1.05, 3.61) 0.02(-0.15, 0.19) 1.24(-0.50, 2.97) 0.03(-0.16, 0.21) 
Calcium supplement ≥3 times/wk 323(17.5)  -1.45(-4.31, 1.41) 0.04(-0.17, 0.26) -1.27(-3.40, 0.86) -0.05(-0.28, 0.18) 
Vitamin D supplement ≥3 times/wk 221(12.1)  0.66(-2.68, 3.99) -0.03(-0.28, 0.22) 1.31(-1.19, 3.80) -0.24(-0.51, 0.03) 
Use of nonthiadize diuretics 26 (1.4)  -1.65(-11.11, 7.80) -0.03(-0.78, 0.72) 0.06(-6.96, 7.08) -0.45(-1.25, 0.35) 
Use of thiadize diuretics 195 (10.5)  1.20(-2.40, 4.80) 0.01(-0.26, 0.28) 0.61(-2.11, 3.32) 0.07(-0.22, 0.36) 
Use of glucocorticoid 12 (0.64)  -2.60(-16.14, 10.9) -0.26(-1.32, 0.79) -3.00(-13.99, 7.99) -0.12(-1.29, 1.06) 
§ Unadjusted 
*Age adjusted only 
¶ Variables with p-value between 0.05 and 0.10 
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Table 4-2 Significant correlates of vBMD in stepwise multiple linear regression models. 
Variables Unit 
Percent change in vBMD per unit change (95%CI) 
Radius Tibia 
Trabecular vBMD1 Cortical vBMD2 Trabecular vBMD3 Cortical vBMD4 
N  1868 1805 1828 1801 
Age (yrs) 10 -3.30 (-4.42, -2.17) -0.70 (-0.81 , -0.60) -0.44 (-1.27 , 0.39)* -0.63 (-0.72 , -0.54) 
Weight (kg) 10 1.83 (1.00, 2.65) -0.28 (-0.34 , -0.22) 4.52 (3.63 , 5.40) -0.31 (-0.38 , -0.25) 
Height (cm) 6.7 -3.87 (-5.06 , -2.68) 0.15 (0.05 , 0.24) -3.96 (-4.83 , -3.07) - 
Grip strength (kg) 10.1 - -0.13 (-0.24, -0.02) -  
Mixed African ancestry  - -0.37 (-0.66 , -0.09) - - 
Diabetes  3.40(0.46, 6.35) 0.39(0.16, 0.61) 5.18 (3.02 , 7.35) 0.41 (0.17 , 0.65) 
Prostate cancer  - -0.26(-0.52, -0.01) - - 
Prostate cancer treatment   - -0.68(-1.19 , -0.18) - -0.86 (-1.40 , -0.33) 
Any fracture  -3.01 (-5.71 , -0.30) - - - 
Smoking      
     Past smoker vs. nonsmoker  -2.95 (-5.57 , -0.33) -0.20 (-0.40 , -0.002) -2.48 (-4.40 , -0.55) - 
     Current smoker vs. nonsmoker  -7.30 (-10.89 , -3.72) -0.28 (-0.55 , -0.004) -4.84 (-7.43 , -2.24) - 
Chew bones >5 days/wk  3.25 (0.25 , 6.25) - 2.32 (0.11 , 4.53) - 
R2  0.06 0.16 0.10 0.13 
1 Age, weight, height, diabetes, prostate cancer treatment, any fracture, smoking status, and bone chewing were enter into the model 
2 Age, weight height, grip strength, caffeine intake (dichotomous), mixed African ancestry, reported/diagnosed prostate cancer, diabetes, prostate 
cancer treatment and  smoking (past and current smoker vs. non smoker) were entered into the model  
3 Age, weigh, height, grip strength, diabetes, systolic blood pressure, daily calcium intake (continuous), smoking (past and current smoker vs. non 
smoker), and bone chewing were entered into the model 
4 Age, weight, grip strength, diabetes, mixed African ancestry, reported/diagnosed prostate cancer, prostate cancer treatment, any fracture, ever 
smoked (dichotomous), and good overall health were entered into the model.  
* P-value> 0.5 (Age was forced into the multiple linear regression model) 
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5.1 ABSTRACT 
Bone mineralization is a tightly controlled process that determines the quality of bone. The 
ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) gene product plays an important 
role in this process. However, very little is known about the potential effect of common variation 
in this gene on bone mineral density (BMD) in humans. The present study aimed to examine the 
associations of 34 single nucleotide polymorphism (SNP) in the ENPP1 gene region with several 
BMD measures in 1,139 Afro-Caribbean men aged ≥40.  Phenotypes included areal BMD 
(aBMD) at the proximal femur and the rate of proximal femur bone loss determined over an 
average of 4.4 years by dual-energy X-ray absorptiometry and trabecular and cortical volumetric 
BMD (vBMD) at the radius and tibia, measured by quantitative computed tomography. The 34 
SNPs captured 77% of the common genetic variation in the ENPP1 gene region. We found that 
SNPs rs6936129 and rs9398995 were associated with accelerated areal bone loss at the femoral 
neck and areal BMD at the total hip (p <0.01). Significant associations (p<0.05) were also 
observed between several SNPs (rs13211931, rs6939185, rs703184, rs7775386, rs9493110, 
rs7769993 and rs9373000, rs1830971, rs858339 and rs7749493) and cortical vBMD. Our 
findings suggest a strong association between common variation in ENPP1 gene and the rate of 
bone loss and BMD in men of African heritage. More studies are needed to confirm and explore 
these relationships in greater detail.    
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5.2 INTRODUCTION 
Osteoblasts mineralize bone matrix by promoting hydroxyapatite crystal formation and growth, 
which provides collagen with structural rigidity and load-bearing strength. Bone mineralization 
is a tightly regulated process that occurs initially in matrix vesicles (MVs) that contain calcium 
and inorganic phosphate ions(Pi)(1,2). Pi crystallizes with calcium to form hydroxyapatite within 
the MVs (3,4). Inorganic pyrophosphate (PPi) determines the rate of hydroxyapatite crystal 
formation in bone by inhibiting the ability of Pi to crystallize. Thus, the balance between levels 
of Pi and PPi is important for normal bone mineralization to proceed(5). Nucleotide 
pyrophosphatase /phosphodiesterase 1, encoded by the ectonucleotide pyrophosphatase 
/phosphodiesterase 1 (ENPP1) gene, is a central regulator of the extracelluar PPi pool and Pi 
level. ENPP1 regulates bone mineralization by generating PPi from nucleotide triphosphates, 
which serves as a source of Pi. The PPi serves further to antagonize the ability of Pi to crystallize 
with calcium to form hydroxyapatite and thereby reduces hydroxyapatite deposition in bone 
matrix (5).  
ENPP1 has been intensively studied as a candidate gene for diabetes, obesity and insulin 
resistance(6-13) due to its ability to inhibit insulin signaling(7). Two meta-analyses have 
reported that individuals who were homozygous for the minor allele of the K121Q 
polymorphism (rs1044498) were more likely to be diabetic(11,14). Recently, studies have 
examined the effect of ENPP1 on bone mineralization in animal models (5,15-20). These studies 
observed hypermineralization and low PPi levels in ENPP1 knockout mice(5,15,19,20). Another 
study found that ENPP1 deficiency effects on mineral deposition might be skeletal site-specific 
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and observed a lower BMD level in the long bones of ENPP1 knockout mice compared to wild-
type mice(20). In the present study, we examined the association between common single 
nucleotide polymorphisms (SNPs) in the human ENPP1 gene and measures of bone mineral 
density and bone loss in a large population of men of African heritage.  
5.3 METHODS 
5.3.1 Study population 
All men were participants in the Tobago Bone Health Study, a study of 2652 community-
dwelling men aged 40 years and older who resided on the island of Tobago. Men who were 
ambulatory, not terminally ill and who had not undergone a bilateral hip replacement were 
recruited between 2000 and 2004 and completed an areal BMD (aBMD) assessment using dual-
energy X-ray absorptiometry (DXA). Details of this study have been described elsewhere(21). In 
2004, participants were asked to return for a follow-up exam and to have a second measure of 
aBMD by DXA. Approximatley 70% of survivors returned for the follow-up exam and 434 new 
participants were also recruited. At this exam, men also completed a peripheral quantitative 
computed tomography (pQCT) scan of the tibia and radius. Blood samples and anthropometric 
measures were also collected and questionnaires about lifestyle and medical factors were 
completed. Samples were batch shipped from Tobago to Pittsburgh for long-term storage by 
overnight shipment with packed dry ice. Genomic DNA was extracted from 5ml frozen blood 
clots (baseline sample) or whole blood (follow-up) using the Qiagen DNA Blood Kit (Qiagen, 
Inc., Valencia, CA). Written informed consent was obtained from each participant using forms 
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and procedures approved by the University of Pittsburgh Institutional Review Board, the U.S. 
Surgeon General’s Human Use Review Board, and the Tobago Ministry of Health. 
5.3.2 Bone Measurements 
Areal BMD (aBMD) at the proximal femur and its subregions was measured by DXA at both the 
baseline and follow-up visits using the same Hologic QDR-4500W densitometer (Hologic Inc., 
Bedford, MA). Technicians followed the same DXA scanning protocol at both visits. The left hip 
was scanned unless fractured or a hip replacement had occurred. Quality control assessments 
were performed weekly to ensure that the scanner was stable throughout the study.  
Volumetric BMD (vBMD) was measured using pQCT (XCT-2000, Stratec 
Medizintechnik, Pforzheim, Germany). pQCT scans were performed at 2 skeletal sites (4% and 
33%) at the non-dominant forearm and left tibia. The scans at the ultra-distal region of radius and 
tibia sites represent predominantly trabecular bone, whereas the scans at the shaft regions 
represent predominantly cortical bone.(22). The radius and tibia were scanned because these two 
skeletal sites are subjected to different weight bearing.  
Technicians followed stringent protocols for patient positioning and scanning. A scout 
view was obtained prior to the pQCT scan to define an anatomic reference line for the relative 
location of the subsequent scans (4% and 33% of the total length) at the radius and tibia. Tibia 
length was measured from the medial malleolus to the medial condyle of the tibia, and forearm 
length was measured from the olecranon to the ulna styloid process. A single axial slice of 
2.5mm thickness with a voxel size of 0.5mm and a speed of 20 mm/s is taken at all locations. 
Image processing was performed using the Stratec software package (Version 5.5E). To 
determine the trabecular vBMD (mg/cm3) at the 4% site of the radius and tibia, identical 
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parameters for contour finding and separation of tabecular and cortical bone were: contour mode 
2, Threshold=169 mg/cm3; peel mode 1, area=45%. To determine the cortical vBMD (mg/cm3) 
at the 33% site of the radius and tibia, identical parameters were: mode 2, Threshold=169 
mg/cm3;cortmode 1, Threshold=710 mg/cm3 
5.3.3 SNP selection 
The ENPP1 gene is located on Chromosome 6 (position 132,170,849-132,257,988) with a size of 
87,140 bps. We used a two-stage strategy to prioritize SNPs for genotyping. First, we employed 
a tagging SNP approach to capture common genetic variation across the ENPP1 gene region. We 
initially identified 149 SNPs across the ENPP1 gene region (including 10kb downstream and 
10kb upstream of the transcript) using publicly available SNP data from Phase II of the 
International HapMap project (http://www.hapmap.org) that were obtained using samples from 
the African Yoruban (YRI) population in Ibadan, Nigeria. A subset of informative SNPs was 
then selected from this larger reference SNP panel using a pair-wise correlation method with r2 
≥0.80 and minor allele frequency (MAF)≥0.05 using the program HClust (23,24). In brief, 
HClust identifies clusters of correlated SNPs. For each cluster, the SNP that is most correlated 
with all other SNPs in the same cluster is then identified as a tag SNP for that particular cluster. 
Using this approach, we identified 52 SNPs (36 singletons and 16 tag SNPs) from the 91 SNPs in 
the reference SNP panel that had a MAF≥0.05.  
We then used the Function Analysis and Selection Tool for Single Nucleotide 
Polymorphisms (FASTSNP)(http://fastsnp.ibms.sinica.edu.tw)(25) and the ElDorado tool 
(version 4.5) from the Genomatix software package (Genomatix Suite release 
3.4; http://www.genomatix.de ) to prioritize the 36 singleton SNPs for genotyping based on their 
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predicted functional effects.  FASTSNP identifies SNPs that may alter: 1) the amino acid in the 
encoded protein to one with different structural characteristics or create a premature termination 
of an amino-acid sequence; 2) an exonic splicing enhancer/silencer binding site in a coding 
sequence that may affect splicing regulation; 3) a consensus splicing site sequence; 4) a putative 
binding site for a transcription factor in the promoter or an intronic region; or 5) a 3’ untranslated 
region motif likely to be involved in post-transcriptional regulation.  ElDorado identifies SNPs 
that may create or abolish a putative transcription factor binding site in the promoter/regulatory 
region of genes by using a large library of weight matrices(26) and was used to analyze 7 SNPs 
that could not be analyzed by FASTSNP. Potentially non-functional singleton SNPs were not 
selected for genotyping leaving 31 SNPs in the panel of tag SNPs.  In addition to these 31 SNPs, 
we also included SNPs that were previously identified to be significantly associated (nominal 
p<0.05) with vBMD in Caucasian men aged ≥65 years in the Osteoporotic Fractures in Men 
Study (MrOS) (27,28). The 6 SNPs that were significantly associated with vBMD in MrOS and 
that had a MAF > 0.05 and that were not monomorphic in YRI samples were selected. The final 
SNP panel included a total of 37 SNPs of interest. 
5.3.4 Genotyping 
Genotyping was performed using pre-designed TaqMan SNP genotyping assays (Applied 
Biosystems). Genotyping was completed according to the manufacture’s protocol on a 7900HT 
Fast Real-Time PCR system (Foster City, CA). The reactions were cycled with standard TaqMan 
conditions (50°C for 2 min hold, 95°C for 10 min hold, 95°C for 15 sec and 60°C for 1 min for 
40 cycles and then cool down to 4°C). The genotypes were called with the Applied Biosystems 
SDS 2.2.2 software package. SNP rs9493119 failed to be manufactured and was replaced by 
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rs9493118 from the same tag SNP cluster. Each SNP was tested for Hardy-Weinberg equilibrium 
(HWE) using a chi-square goodness-of-fit test. Three SNPs (rs9493105, rs7773477 and 
rs9493116) were not in Hardy-Weinberg Equilibrium (p< 0.001) and were dropped from further 
analysis. Two of these SNPs (rs9493105 and rs7773477) had no replacement and one SNP 
(rs9493116) was replaced by rs7769712 from the same cluster. SNP rs9402345 had a MAF < 
0.05 in our population and was removed from the analysis. Our final working genotype set 
consisted of 34 SNPs. The average genotyping completeness rate was 95.9%. The average 
genotyping consensus rate among the 5% blind replicate samples was 99.4% with individual 
consensus rates for all SNPs ≥97.2%. We estimated using the program Tagger 
(http://www.broad.mit.edu/mpg/haploview (29) that the 34 genotyped SNPs captured 77% of the 
common variation in the ENPP1 gene region . 
5.3.5 Statistical analysis 
All single SNP associations were tested assuming additive, dominant and recessive inheritance 
models using linear regression or analysis of covariance (ANCOVA). For the additive model, a 
linear regression model was constructed to test whether carrying 0, 1, or 2 minor alleles had a 
linear effect on the bone related trait. The continuous phenotypes were regressed on the allele 
count (0, 1, 2). For dominant (AA vs. AB+BB) and recessive (AA+AB vs. BB) inheritance 
models, ANCOVA was used to test the association between genotype and phenotype. All models 
were adjusted for age, weight and height. We also performed multiple-testing correction of p-
values with permutation using R project (http://www.r-project.org). Study-wise p-values were 
obtained empirically for each phenotype with the consideration of the best inheritance models 
associated with each SNP. This p-value represented the overall impact of the 34 genotyped SNPs 
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on the selected phenotype, rather than any particular SNP. Statistical analysis was performed 
using the Statistical Analysis System (SAS, version 9.1; SAS Institute, Cary, NC).  
5.4 RESULTS 
The population sample consisted of 1,139 Afro-Caribbean men aged 40 and older who self-
reported non-mixed African ancestry. Their mean (± SD) age was 58.7 ± 10.1 years (Table 5-1). 
Information on the 34 genotyped ENPP1 SNPs, including NCBI dbSNP reference number, 
chromosome position, major and minor alleles, minor allele frequencies in Tobago and Yoruban 
(YRI) population from Ibadan, Nigeria from Phase II of the International HapMap project 
(www.hapmap.org) and number of subjects with each genotype in current study, and tests of 
HWE are shown in Table 5-2. Minor allele frequencies were very comparable to those in the 
YRI sample from the HapMap project and all SNPs were in HWE in the current study (P>0.01). 
The results of single SNP association analyses and rate of change in aBMD during the 4.4 years 
of follow-up are shown in Figure 5-1 and Table 5-3. We plotted the transformed (-log10) p-
values from the best fitting model for each SNP. We further summarized the results for SNPs 
that were significantly associated with the rate of change in aBMD (nominal p<0.05). Of the 34 
SNPs tested, only one SNPs(rs9398995) was associated with bone loss at the total hip (nominal 
p< 0.05). For this SNP, men who were homozygous for the minor allele experienced twice the 
rate of decline in aBMD than those who were homozygous for the major allele. At the femoral 
neck, there were five additional SNPs that showed a significant association with the rate of 
decline in aBMD with a nominal p <0.05. Except for rs2021966, the minor alleles for all the 
other 4 SNPs were associated with a greater decline in aBMD. The strongest SNP association 
  110
was for rs6936129, where the best fitting model was additive (p=0.0035). Men who where 
homozygous for the minor allele of this SNP experienced a 2.5-fold greater rate of decline in 
aBMD compared to those who were homozygous for the major allele, whereas men who were 
heterozygous experienced a more intermediate rate of bone loss.   
The SNP association results with cross-sectional areal and volumetric BMD measures are 
presented in the same format in Figure 5-2 and Table 5-4. For the aBMD measures, nominally 
significant associations were only observed at the total hip, but not femoral neck. Three SNPs 
achieved nominal significance for aBMD at the total hip with rs9398995 showing to strongest 
evidence of association in the recessive inheritance model (p=0.0063). Men who were 
homozygous for the minor allele had approximately 0.05 g/cm2 lower hip aBMD than those who 
were homozygous for the major allele. Similar to the results for the decline in aBMD, SNPs 
associated with total hip BMD in cross-sectional analyses were largely concentrated in the 5’ 
flanking region and intron 1 of ENPP1.  
Significant associations between vBMD were more likely to be observed in cortical than 
trabecular vBMD (Figure 5-2 and Table 5-4). For cortical vBMD, 7 SNPs (rs13211931, 
rs6939185, rs703184, rs7775386, rs9493110, rs7769993 and rs9373000) at the radius and 4 
SNPs (rs13211931, rs1830971, rs858339 and rs7749493) at the tibia were significant at p<0.05. 
SNP rs13211931 showed the strongest association with cortical vBMD at the tibia and was the 
only SNP with a significant association with cortical vBMD at both the radius and tibia. For 
example, men who had two copies of the minor allele had 12 mg/cm3 or approximately ½ 
standard deviation lower cortical vBMD at the radius compared to men who were homozygous 
for the major allele.  
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The associations between ENPP1 SNPs and trabecular vBMD were not as strong as they 
were for cortical vBMD. Similar to rs13211931, rs6916495 was associated with trabecular 
vBMD at both the radius and tibia. The effect of this SNP on trabecular vBMD appeared to be 
best modeled as a recessive mode of inheritance. For instance, men who were homozygous for 
the minor allele had an approximately 12-13% and 8-9% or approximately ½ standard deviation 
lower trabecular vBMD at the radius and tibia, respectively, than those with the other genotypes.  
Nine of the SNPs that showed significant results among Caucasians in the MrOS study 
(nominal p <0.05) did not seem to have very strong associations with any of the BMD measures 
in the Afro-Caribbean men. Four of the 9 SNPs (rs6939185, rs858339, rs6916495 and 
rs7768480) had a nominal p<0.05.  
The study-wise empirical p-value generated from the permutation test for each phenotype 
was between 0.0014 and 0.0017. Thus, none of our single SNP associations with bone loss or 
BMD remained significant after the correction for multiple testing. 
5.5 DISCUSSION 
Osteoporosis is a common disorder characterized by a loss of bone mineral and structure leading 
to compromised bone strength. Despite the lower prevalence of osteoporosis in men than 
women, the number of older men with low BMD is still substantial(30). Evidence from twin and 
family studies indicates that the heritability for aBMD ranges from 50% to 85% (31-33). 
Although most of the heritability studies for aBMD were in Caucasians, men and women of 
African heritage also have a high heritability of aBMD (34). In contrast to the heritability of 
cross-sectional measures of aBMD, the heritability of bone loss is less well defined. Nonetheless, 
  112
heritability estimates for bone loss with age range from 15% to 45% (35-38). Although previous 
studies have demonstrated an important role of ENPP1 in bone mineralization in animal models, 
the effect of ENPP1 gene variation on aBMD and bone loss in humans is unknown. Our results 
suggest a novel association between common ENPP1 allelic variation and aBMD and the rate of 
bone loss in men of African heritage. 
Most association and linkage studies of BMD in humans have relied solely on DXA 
measures of areal BMD as the phenotype. DXA provides a two-dimensional measure of BMD 
and is known to be confounded by bone size. Furthermore, DXA yields a measure of integral 
BMD – trabecular and cortical BMD combined. On the other hand, 3-dimensional QCT enables 
a separate measure of volumetric BMD in the trabecular and cortical bone compartments. 
Although less well studied than DXA measures of aBMD, a high heritability has been 
demonstrated for trabecular vBMD (~70%) (34,39) and there is evidence for both shared and 
unique loci for cortical and trabecular vBMD (34). However, the genetic variants contributing to 
vBMD variation remain poorly defined. Results from the current study suggest a role of genetic 
variation in ENPP1 in determining vBMD with more consistent effects on cortical than 
trabecular vBMD. 
Although our study is the first, to our knowledge, to investigate ENPP1 and measures of 
bone health, other studies have investigated this gene in relation to other disease related end-
points. In studies of humans, SNP rs1044498 which creates a missense substitution was found to 
be related to arterial calcification (40-42), osteoarthritis(18) and ossification of posterior 
longitudinal ligament of the spine(43). This SNP has also been associated with diabetes (6,10-
14). In the current study, we have found no significant association between this particular amino 
acid substitution and measures of aBMD, vBMD or the rate of hip bone loss. 
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SNP rs6936129 in the promoter region was highly and significantly associated with 
femoral neck bone loss with evidence of an additive mode of inheritance. Although there were 
only 13 men homozygous for the minor allele of rs6936129, the 180 men who were 
heterozygous for this variant also experienced 55% greater bone loss than those who were 
homozygous for the major allele. This SNP is predicted in silico by FASTSNP to create a 
putative binding site for the pro-inflammatory transcription factor, STAT, which may regulate 
expression of ENPP1 in response to cytokines. 
 Only one SNP, rs9398995, showed a strong association with aBMD at the total hip. This 
SNP is located in intron 1 and is predicted to generate a putative binding site for the homeobox 
transcription factor, CDXA, which is not known to regulate ENPP1 gene expression. There were 
five SNPs that were associated with cortical vBMD at p<0.01 (rs13211931, rs7749493, 
rs703184, rs9493110 and rs9373000). None of these five SNPs were in the same linkage 
disequilibrium (LD) blocks defined by using a solid spline approach (D’>0.80) to analyze Phase 
II HapMap SNPs in the Yoruban population from Nigeria, Africa. SNPs rs13211931 and 
rs7749493 were associated with cortical vBMD at the tibia, whereas rs703184, rs9493110 and 
rs9373000 had strong associations with cortical vBMD at the radius. SNP rs7749493 lies in 
intron 5 of ENPP1 and is predicted to create a putative biding site for the transcription factor, 
RUNX1/CBFA2/AML1, which is involved in skeletal development. SNP rs703184 lies in intron 
1 of ENPP1 and is predicted to create a putative binding site for the SRY-related high-mobility-
group box (SOX) family of transcription factors. The SOX family controls cell fate and 
differentiation and plays a role in skeletogenesis (44). 
Although a high heritability of trabecular vBMD was observed in previous studies 
(34,39), no SNP in ENPP1 appeared to be associated with trabecular vBMD at a p<0.01. Among 
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the 9 SNPs that showed a statistically significant association with vBMD (p<0.05) at the femoral 
shaft among Caucasian men in the MrOS study, only 4 were associated with aBMD or vBMD in 
our study of Afro-Caribbean men. However, none of these SNPs were associated at p<0.01. The 
low level of concordance between SNPs and BMD between two studies may be explained by the 
different linkage disequilibrium patterns Caucasian and African individuals, different skeletal 
sites studied or differences in the characteristics of the cohorts. Nonetheless, our results suggest a 
“gene level” replication of associations between common genetic in ENPP1 and BMD in men of 
diverse ethnicity/race. 
Our study has several notable strengths including its large cohort of middle- and older- 
aged men who were recruited from a relatively homogeneous population. In addition, we 
identified and genotyped 34 SNPs across the gene region which provide good coverage of the 
common genetic variation in the ENPP1 gene. Our study also had limitations. We evaluated a 
large number of SNPs, several skeletal phenotypes and tested for 3 models of inheritance for 
each SNP and phenotype. None of our SNPs achieved statistical significance after controlling for 
multiple comparisons and our results will require replication and further evaluation in a larger 
sample size and in additional populations.   
In conclusion, our study suggests a possible novel role of common genetic variation in 
ENPP1 and several measures of bone health including areal BMD, volumetric BMD and the rate 
of bone loss in a large male cohort of African ancestry. This is the first study to examine the 
association between ENPP1 gene variation and BMD in humans. Additional studies are needed 
to explore the association between ENPP1 gene variants, bone mineralization and BMD. 
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Table 5-1 Selected characteristics of Afro-Caribbean men (n=1139) 
Characteristics Mean ± SD 
Age (yrs) 58.7 ± 10.1 
Height (cm) 175.2 ± 6.8 
Weight (kg) 84.0 ± 14.4 
BMI (kg/m2) 27.3 ± 4.2 
Annualized rate of change in BMD (%/yr)  
Total hip BMD -0.118 ± 0.562 
Femoral neck BMD -0.296 ± 0.823 
Proximal femur area BMD (g/cm2)  
Total hip BMD (g/cm2) 1.157 ± 0.145 
Femoral neck BMD (g/cm2) 1.000 ± 0.149 
Trabecular volumetric BMD (mg/cm3)  
Radius 207.2 ± 49.2 
Tibia 229.4 ± 40.4 
Cortical volumetric BMD (mg/cm3)  
Radius  1214.8 ± 22.6 
Tibia 1179.0 ± 23.1 
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Table 5-2 Information on the genotyped SNPs in the ENPP1 gene  
dbSNP rs 
number 
Major/ 
minor 
allele 
Chrom. 
Position 
(bp) 
MAF N in each genotype* HWE 
p-value Afro-Caribbean YRI NN Nn Nn 
rs7773292 C/T 132141454 0.22 0.19 681 349 60 0.069 
rs6925433 A/G 132161059 0.19 0.21 713 309 46 0.071 
rs13211931 G/T 132165417 0.09 0.09 897 177 12 0.328 
rs6935458 A/G 132168013 0.43 0.43 373 501 223 0.021 
rs6936129 G/C 132168133 0.09 0.07 875 168 13 0.130 
rs6569759 G/A 132174809 0.23 0.28 658 378 71 0.095 
rs6939185 G/A 132180880 0.09 0.11 917 180 14 0.131 
rs9398995 T/C 132181896 0.21 0.18 702 337 55 0.065 
rs943004 G/A 132182569 0.23 0.13 656 405 49 0.174 
rs1830971 T/C 132190046 0.25 0.23 615 412 72 0.714 
rs1409181 C/G 132190993 0.29 0.30 560 457 97 0.729 
rs2021966 T/C 132192132 0.29 0.28 556 452 100 0.546 
rs7771841 G/A 132192798 0.21 0.20 678 366 51 0.773 
rs9372999 C/A 132194845 0.27 0.29 575 411 79 0.631 
rs858338 G/T 132194900 0.13 0.12 843 240 20 0.542 
rs858339 T/A 132195590 0.32 0.24 521 473 124 0.261 
rs703184 G/C 132196688 0.10 0.09 898 187 12 0.540 
rs7775386 C/T 132198842 0.49 0.44 296 528 270 0.246 
rs6916495 C/T 132201958 0.11 0.09 867 210 16 0.421 
rs9493110 C/T 132203671 0.24 0.32 620 423 58 0.197 
rs858345 G/A 132205310 0.35 0.34 458 475 141 0.301 
rs4141767 A/G 132206700 0.41 0.41 389 521 183 0.687 
rs6926970 A/C 132208983 0.19 0.15 729 321 55 0.013 
rs1044498 C/A 132214061 0.13 0.08 856 205 29 0.483 
rs7749493 G/T 132216752 0.23 0.19 665 362 69 0.032 
rs17060836 T/C 132230641 0.23 0.25 630 395 53 0.379 
rs7769712 A/C 132235088 0.32 0.32 478 463 99 0.397 
rs7768480 G/A 132245125 0.46 0.42 339 522 251 0.062 
rs12202373 T/C 132251394 0.08 0.10 916 151 12 0.045 
rs9493118 C/T 132253058 0.32 0.31 518 455 124 0.112 
rs1804025 A/G 132253227 0.23 0.20 669 366 73 0.019 
rs7754561 G/A 132254387 0.11 0.07 851 207 20 0.078 
rs7769993 A/G§ 132262945 0.43 0.47 371 520 210 0.240 
rs9373000 A/G 132263399 0.38 0.44 433 508 163 0.471 
§ The major allele in YRI population was G allele 
*NN/Nn/nn: N=major allele; n=minor allele 
Chrom indicates position on chromosome 6 from NCBI Genome Build 36; MAF, minor allele frequency; YRI, 
Yoruban population from Ibadan, Nigiria; HWE; Hardy-Weinberg Equilibrium.    
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Figure 5-1 Schematic of negative log 10 of p-value for 34 single SNP association tests with longitudinal aBMD changes at the total hip and femoral neck.  
ENPP1 SNPs are represented on the X axis according to their positions in the gene from 5’ to 3’ direction. Dotted lines represent p-value thresholds of 0.05, 0.01 
and 0.001. The smallest p-value for each SNP is plotted. Models were adjusted for age, weight and height. THABC: Total hip annualized aBMD change rate; and 
FNABC: Femoral neck annualized aBMD change rate. 
   p<0.001 
p<0.01 
p<0.05 
ENPP1 gene 
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Table 5-3 Association of ENPP1 SNPs and rate of decline in aBMD per year (%/yr) 
SNP Genotype mean(standard error) p-value Best fitting model 1/1 1/2 2/2 
Total hip      
    rs9398995 -0.100(0.021) -0.125(0.030) -0.262(0.074) 0.0423 Recessive 
Femoral neck      
    rs7773292 -0.291(0.031) -0.288(0.043) -0.514(0.104) 0.0366 Recessive 
    rs6935458 -0.253(0.042) -0.290(0.036) -0.379(0.054) 0.0383 Additive 
    rs6936129 -0.269(0.027) -0.417(0.062) -0.679(0.223) 0.0035 Additive 
    rs2021966 -0.308(0.034) -0.326(0.038) -0.115(0.081) 0.0177 Recessive 
    rs858338 -0.279(0.028) -0.312(0.052) -0.727(0.180) 0.0156 Recessive 
Genotype-specific means were adjusted for age, weight and height. 
1 indicates major allele; 2 minor allele. 
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Figure 5-2 Schematic of negative log 10 of p-value for 34 single SNP association tests with cross-sectional aBMD at the total hip and femoral neck, and 
trabecular and cortical vBMD at the radius and tibia.  
ENPP1 SNPs are represented on the X axis according to their positions in the gene from 5’ to 3’. Dotted lines represent p-value thresholds of 0.05, 0.01 and 
0.001. The smallest p-value for each SNP is plotted. Models were adjusted for age, weight and height. THBMD: Total hip aBMD; FNBMD: femoral neck 
aBMD; RTRBD: trabecular vBMD at the radius; RCRTD: cortical vBMD at the radius; TTRBD: trabecular vBMD at the tibia; and TCRTD: cortical vBMD at 
the tibia. 
p<0.001 
p<0.01 
p<0.05 
ENPPP1 gene 
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Table 5-4 Association of ENPP1 SNPs and bone mineral density  
SNP Genotype Mean(standard error) p-value Best fitting model 1/1 1/2 2/2 
Total hip aBMD (g/cm2)     
    rs6925433 1.156(0.005) 1.156(0.007) 1.198(0.019) 0.0338 Recessive 
    rs9398995 1.159(0.005) 1.160(0.007) 1.110(0.018) 0.0063 Recessive 
    rs1830971 1.159(0.005) 1.159(0.006) 1.128(0.015) 0.0470 Recessive 
Radius trabecular vBMD (mg/cm3)     
    rs6916495 208.1(1.635) 207.4(3.324) 181.6(12.040) 0.0294 Recessive 
    rs7769993 207.4(2.489) 205.9(2.102) 213.9(3.309) 0.0460 Recessive 
Radius cortical vBMD (mg/cm3)     
    rs13211931 1214.0(0.704) 1217.4(1.586) 1225.4(6.084) 0.0147 Additive 
    rs6939185 1215.3(0.694) 1213.5(1.57) 1203.8(5.619) 0.0380 Additive 
    rs703184 1215.5(0.703) 1213.8(1.544) 1203.3(6.078) 0.0049 Additive 
    rs7775386 1216.3(1.224) 1215.5(0.916) 1212.4(1.282) 0.0201 Recessive 
    rs9493110 1213.2(0.847) 1216.9(1.025) 1216.5(2.782) 0.0046 Dominant 
    rs7769993 1213.0(1.095) 1216.5(0.925) 1215.1(1.456) 0.0215 Dominant 
    rs9373000 1212.6(1.009) 1216.4(0.931) 1215.9(1.643) 0.0047 Dominant 
Tibia trabecular vBMD (mg/cm3)     
    rs6935458 232.7(2.011) 228.0(1.736) 226.8(2.608) 0.0416 Dominant 
    rs6916495 230.2(1.323) 227.2(2.689) 209.8(9.741) 0.0429 Recessive 
    rs7768480 228.3(2.104) 227.6(1.695) 234.8(2.445) 0.0137 Recessive 
Tibia cortical vBMD (mg/cm3)     
    rs13211931 1178.1(0.730) 1183.2(1.646) 1185.6(6.314) 0.0026 Additive 
    rs1830971 1180.2(0.876) 1177.7(1.071) 1176.7(2.558) 0.0492 Dominant 
    rs858339 1177.9(0.950) 1180.8(0.997) 1179.6(1.941) 0.0450 Dominant 
    rs7749493 1179.1(0.845) 1177.8(1.144) 1186.2(2.627) 0.0055 Recessive 
Genotype-specific means were adjusted for age, weight and height. 
1 indicates major allele; 2, minor allele; aBMD, areal BMD; vBMD, volumetric BMD 
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6.0  GENERAL DISCUSSION 
6.1 SUMMARY 
Osteoporosis is a growing public health problem in men of all races and ethnicities. Much less is 
known about age-related bone loss and osteoporosis in men relative to women, especially in men 
of African heritage. This dissertation investigated the determinants of bone mineral density in a 
large cohort of Afro-Caribbean men aged 40 and older from the Tobago Bone Health Study. 
Three broad aims of this dissertation project were to: 1) examine the patterns and determinants of 
longitudinal age-related hip bone loss measured by DXA; 2) examine the age-related pattern and 
correlates of volumetric BMD and to compare and contrast findings for trabecular and cortical 
vBMD measured by pQCT;, and 3) evaluate the relationship of polymorphisms in the ENPP1 
gene with bone loss and BMD.  
In the bone loss analyses, we observed that men of African descent had a comparable rate 
of decline in hip BMD to published data in Caucasian men (2-4,6,8) and the rate of bone loss 
across 5-year age groups appeared to have a U-shape relationship. Men aged 40-44 had a 
significantly greater rate of decline in BMD than those aged 45-49 and 50-54 at both the total hip 
and femoral neck. Thereafter, the rate of decline in BMD accelerated with advancing age through 
the 7th decade. We also identified low body weight, weight loss, prostate cancer and androgen 
deprivation treatment for prostate cancer as potential determinants of accelerated bone loss in 
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this population.  However, the variation in rate of bone loss explained by these factors was only 
6% to 7%.  Our study also confirmed the modulating effects of weight loss and older age on 
bone loss that has been observed in previous studies of Caucasian men (3,5-7,73). 
In the analysis of vBMD, we observed a non-linear reduction of trabecular vBMD with 
aging where a larger decline was found among men aged 40-44 and 45-49 years, compared with 
those aged 50 and older. This finding is consistent with the recent observation of an early 
reduction of trabecular vBMD with aging in Caucasian men (131,134). In contrast, cortical 
vBMD appeared to decline more slowly and steadily with aging than trabecular vBMD, which 
was also observed in another study (131). Body weight appeared to be a protective factor for 
trabecular vBMD but a risk factor for cortical vBMD. The reverse relationship between body 
weight and cortical vBMD is consistent with another recent study (153). Diabetes and bone 
chewing were also identified as beneficial correlates of vBMD, whereas cigarette smoking, 
prostate cancer and treatment for prostate cancer with androgen deprivation were identified as 
potential risk factors for lower vBMD. Moreover, these determinants did not have the same 
effects on vBMD across different skeletal sites and only explained 6% to 16% variation in 
vBMD.  
In the genetic analysis, several polymorphisms in the ENPP1 gene were found to be 
associated with bone loss and areal and volumetric BMD independent of age, weight and height. 
For femoral neck bone loss, total hip BMD and trabecular vBMD, only one SNP was associated 
with each of these phenotypes with a nominal p-value<0.01. However, there were 4 SNPs that 
appeared to have strong association with cortical vBMD at P<0.01. The commonly tested 
missense SNP in ENPP1 (rs1044498) that has been associated with insulin resistance and 
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abnormal calcification (150,151,154-158) was not associated with any BMD measures in our 
study.   
6.2 CONCLUSIONS AND FUTURE RESEARCH DIRECTIONS 
Our study sought to determine potential demographic, anthropometric, medical, behavioral and 
genetic factors associated with bone loss and BMD in a large cohort of men with a high African 
ancestral proportion. Our study also used a unique imaging scan data obtained by pQCT that 
provided a true measure of volumetric BMD for cortical and trabecular bone. To our knowledge, 
this is first study to examine the age-related patterns and determinants of trabecular and cortical 
vBMD, and the second and largest study to examine age-related bone loss and its determinants in 
a group of middle- and older age men of African descent. This is also the first study, to our 
knowledge, to examine the relationship between ENPP1 gene variants and vBMD in men of 
African descent.   
Indeed, we were able to demonstrate a significant rate of decline in BMD among this 
population despite their high BMD and low osteoporosis risk.  We also identified several 
anthropometric, behavioral and medical factors that may be associated with accelerated bone loss 
and lower vBMD. However, these factors only account for a small proportion of the variation in 
age-related bone loss and vBMD. This suggests that many other underdetrtmined variables, 
including inherited factors, may contribute to age-related bone loss and vBMD. We were also 
able to establish an association of SNPs in the ENPP1 gene with bone density, especially cortical 
vBMD, and the rate of hip bone loss in this cohort.  
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Our study had several potential limitations including: 1) a small proportion of older-aged men 
that may have limited our ability to estimate age-related patterns in vBMD and the rate of bone 
loss among these older men; 2) DXA measures of bone loss that are unable to provide insight on 
age-related loss of trabecular and cortical bone; 3) questionnaire assessments of medical and 
behavioral history that may be subject to recall bias and misclassification; 4) cross-sectional 
measures of vBMD that limits our ability to establish temporal relationships with trabecular and 
cortical vBMD;  and 5) the use of multiple SNPs and inheritance models to test the association 
between ENPP1 gene variants and bone measures generates issues of multiple comparisons and 
possible false positive findings;However, our study also had notable strengths including: 1) its 
large sample size and focus on men of African descent with low Caucasian admixture; 2) careful 
measurement of variables; 3) focus on both cortical and trabecular volumetric BMD; and 4) the 
wealth of information available about the study cohort. Our results validated associations 
described previously among Caucasian men, such as the major importance of body weight in 
determining BMD and bone loss, but also illuminate several previously unrecognized 
relationships. 
     Additional longitudinal studies are needed to confirm our findings of a non-linear 
relationship of age and bone loss in men of African heritage. Specially, the impact of aging on 
trabecular and cortical volumetric BMD in this population deserves further investigation. 
Although osteoporosis largely occurs later in life, there is a need to recruit younger adults for 
longitudinal studies of bone loss. With the increasing body of evidence showing that 
development of osteoporosis and osteoporotic factures is due to factors other than or in addition 
to low bone density, it will be important to characterize other bone health parameters, such as 
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cortical and trabecular thickness and bone structural geometry and to identify the behavioral and 
genetic determinants of these parameters. In addition, more studies are also needed to understand 
the differences in trabecular and cortical bone loss with aging and the correlates of this loss 
including behavioral/lifestyle and medical characteristics, and hormonal and genetic factors.  
This information will ultimately help us to better understand the natural history and 
etiology of osteoporosis and osteoporotic fractures as well as the underlying factors for racial 
differences in male skeletal health.   
6.3 PUBLIC HEALTH SIGNIFICANCE 
Osteoporosis, an important risk factor of osteoporotic fractures, is a public health problem that is 
not only prevalent in women but also in men. In the US alone, 1-2 million Caucasian men are 
affected with osteoporosis, and another 8-13 million are affected with osteopenia (20). As 
lifespan increases worldwide in the next several decades, the prevalence of osteoporosis and its 
associated fractures is expected to increase significantly not only among Caucasians, but also 
among people of African descent (21-23). In addition, despite the lower prevalence of 
osteoporosis and fractures in people of African ancestry, a higher mortality after a fracture has 
been observed among African Americans and men, compared to Caucasians and women 
(1,26,27). Moreover, the direct medical costs for osteoporotic fractures is greater than the 
projected annual cost of stroke, breast cancer, diabetes, or chronic lung disease (30) and the total 
cost due to osteoporotic fractures is predicted to increase more in African Americans than 
Caucasians (28).  
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Identifying factors associated with the rate of bone loss and low BMD may facilitate the 
development of strategies to better prevent osteoporosis. Our study revealed that men of African 
descent may have a comparable rate of hip bone loss with Caucasian men, and also confirmed an 
important role of low body weight and its weight loss in accelerated bone loss with age which 
are both potentially modifiable risk factors.  
We reported in our study that behavioral factors only account for a small proportion of 
the variation in vBMD and rate of decline in aBMD. With the high heritability observed in BMD 
(11-13) , it is likely that genetic factors contribute greatly to the remaining unexplained variation. 
The present study also demonstrated a relationship of allelic variants in ENPP1, a gene involved 
in bone mineralization, with BMD and bone loss. Further research on the genetic susceptibility to 
low bone density and accelerated bone loss may help to identify new therapeutic targets to treat 
or prevent osteoporosis.  
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